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ABSTRACT 
 
The Cancer stem cell (CSC) model became an attractive concept to explain 
several poorly understood clinical phenomena due to its inherent theoretical 
properties. Such properties are based on the molecular features of normal stem 
cells (SCs). Thus, CSCs are believed to have the ability to renew themselves and 
to last a lifetime and to be resistant to electromagnetic and chemical insults. This 
resistance ability allows them to stagnate for long periods of time and 
consequently, to colonize other parts of the body. With this notion, a search for 
specific surface and intracellular biomarkers has been ongoing in recent years for 
the identification, isolation and characterization of CSCs in several cancers, like in 
breast cancer. In fact, breast cancer stem cells (BCSCs) were initially defined by 
the presence and absence of the cell-surface proteins CD44 and CD24, 
respectively. The CD44+/CD24-/low phenotype has been demonstrated to have 
tumor initiating properties and has been associated with stem cell-like 
characteristics, enhanced invasive properties, radiation resistance and with distinct 
genetic profiles suggesting an association with adverse prognosis. However, and 
due to the high levels of heterogeneity associated with this disease, some breast 
tumors were shown not to harbor any CD44+/CD24-/low breast cell. As a 
consequence, additional SC markers like ALDH1 have been reported. 
Hence, our first goal in this study was to compare by immunohistochemistry 
(IHC), two of the most reliable SC markers ALDH1 and CD44 and to correlate their 
expression in different breast lesions. Moreover, we combined these markers with 
Ki-67 to evaluate quiescence and to identify, assess its distribution and estimate 
the mean percentages of CD44+/ALDH1+/Ki-67- cells in non-malignant and 
malignant lesions.  
CD44 and ALDH1 expression was commonly observed in distinct breast 
lesions and a higher combined expression of these markers was noticed in ductal 
carcinomas in situ (DCIS) when compared with invasive ductal carcinomas (IDCs). 
Such result was subsequently strengthened by the enrichment of 
CD44+/ALDH1+/Ki-67- tumor cells observed in DCIS. Besides that, our results also 
demonstrated that this phenotype may favor distant metastasis being able of 
predicting overall survival (OS).  
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Despite these results, the CD44+/CD24-/low phenotype continues to be by far 
the most studied phenotype in breast cancer. The latter was recently associated 
with epithelial-mesenchymal transition (EMT) markers and was demonstrated to 
have several signaling pathways dysregulated. Thus, massive parallel sequencing 
(MPS) can be regarded as an interesting approach to deepen the molecular 
characterization of CD44+/CD24-/low cells since it allows the analysis of hundreds of 
genes in just one population of cells. In fact, standardized Next-Generation 
Sequencing (NGS) kits are currently available providing reliable sequencing 
results in routine cancer diagnostics, like the Ion Torrent Cancer Hotspot Panel v2 
(CHPv2). Such assay includes 50 genes known to be involved in the pathogenesis 
of many human cancers.  
In this way, our second goal was to characterize CD44+/CD24-
/Cytokeratin(Ck)+/CD45- cells through flow cytometry (FCM) in a cohort containing 
non-malignant and malignant breast lesions. The CHPv2 assay was used for the 
identification of somatic mutations in the DNA extracted from isolated 
CD44+/CD24-/Ck+/CD45- cells. The expression of E-Cadherin and vimentin was 
also analyzed in the malignant lesions. 
 The percentage of CD44+/CD24-/Ck+/CD45- cells increased significantly 
from non-malignant to malignant lesions and was negatively correlated with tumor 
size. A significant association with vimentin was also observed. From the MPS 
analysis, the non-malignant lesion harbored only a single-nucleotide polymorphism 
(SNP). Mutations in the tumor suppressor p53 (TP53), NOTCH homolog 1 
(NOTCH1), Phosphatase and tensin homolog (PTEN) and v-akt murine thymoma 
viral oncogene homolog 1 (AKT1) genes were found in isolated CD44+/CD24-
/Ck+/CD45- cells from DCIS. Additional mutations in the colony-stimulating factor 1 
receptor (CSF1R), ret proto-oncogene (RET) and TP53 genes were also identified 
in IDCs.  
In conclusion, CD44+/ALDH1+/Ki-67- tumor cells may have a higher 
tumorigenic effect in breast cancer than CD44+/CD24-/low tumor cells. Due to its 
role, ALDH1 can be determinant for the behavior of BCSCs, for their ability to 
resist to chemotherapeutic agents and their dissemination to other parts of the 
body, which can be aided by the role of CD44. Additionally, quiescence seems to 
be crucial for tumor progression, resistance to chemotherapeutic agents and 
metastatic spread of BCSCs. Further studies to infer about the tumorigenic and 
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metastatic ability of CD44+/ALDH1+/high tumor cells combined with their quiescence 
status still have to be depicted. 
The characterization of CD44+/CD24-/Ck+/CD45- cells supports the 
existence of a tumor initiation capability from these cells which can be 
strengthened by the acquisition of an EMT state. All of the mutated genes that 
were found in this study can play important roles for the development and 
transformation of CD44+/CD24-/Ck+/CD45- breast cells into a malignant 
phenotype, for stemness maintenance and activation of the EMT state. Functional 
analyses are now required to determine the tumorigenic effect of each mutation. 
Subsequent applications of NGS technologies are also demanded to better 
understand the malignant progression of breast stem cells (BSCs) and to design 
an effective mutational profile of these cells. 
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RESUMO 
 
O modelo das células estaminais cancerosas tornou-se num conceito 
atractivo para explicar vários fenómenos clínicos pobremente compreendidos 
devido às suas propriedades teóricas inerentes. Tais propriedades baseiam-se 
nas características moleculares das células estaminais normais. Deste modo, 
acredita-se que as células estaminais cancerosas são capazes de se renovarem e 
de durarem uma vida inteira e de serem resistentes aos insultos químicos e 
electromagnéticos. Esta capacidade de resistência permite-lhes estagnar por 
longos períodos de tempo e consequentemente, de colonizarem outras partes do 
corpo. Com esta noção, tem sido feito nos últimos anos uma procura por 
biomarcadores de superfície e intracelulares específicos para a identificação, 
isolamento e caracterização das células estaminais cancerosas em vários tipos de 
cancros, como no cancro da mama. De facto, as células estaminais cancerosas 
da mama foram inicialmente definidas pela presença e ausência das proteínas de 
superfície celular CD44 e CD24, respectivamente. O fenótipo CD44+/CD24-/baixo foi 
demonstrado ter propriedades de iniciação tumoral e tem sido associado com 
características típicas das células estaminais, propriedades invasoras 
aumentadas, resitência à radiação e com distintos perfis genéticos que sugerem 
uma associação com um prognóstico adverso. No entanto e devido aos elevados 
níveis de heterogeneidade associados com esta doença, alguns tumores da 
mama foram demonstrados não conter nenhuma célula CD44+/CD24-/baixo. 
Consequentemente, outros marcadores de células estaminais foram reportados 
como o ALDH1.    
Deste modo, o nosso primeiro objectivo neste estudo foi comparar, por 
imunohistoquímica, dois dos marcadores de células estaminais mais fiáveis, o 
ALDH1 e o CD44 e correlacionar as suas expressões em diferentes lesões da 
mama. Mais ainda, combinámos estes marcadores com o Ki-67 para avaliar a 
quiescência e para identificar, determinar as suas distribuições e estimar as 
percentagens das células CD44+/ALDH1+/Ki-67- em lesões benignas e malignas.   
A expressão do CD44 e do ALDH1 foi comummente observada em 
diferentes lesões da mama e uma elevada expressão combinada destes 
marcadores foi observada em carcinomas in situ quando comparada com 
carcinomas invasores. Este resultado foi subsequentemente reforçado pelo 
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enriquecimento de células tumorais CD44+/ALDH1+/Ki-67- verificado nos 
carcinomas in situ. Além disso, os nossos resultados também demonstraram que 
este fenótipo pode favorecer metástases à distância sendo capaz de prever a 
sobrevida global.  
Apesar destes resultados, o fenótipo CD44+/CD24-/baixo continua a ser de 
longe o fenótipo mais estudado no cancro da mama. Este último foi recentemente 
associado com marcadores de transição epitélio-mesenquimal e foi demonstrado 
ter várias vias de sinalização desreguladas. Assim sendo, a sequenciação 
massiva em paralelo pode ser vista como uma abordagem interessante para 
aprofundar a caracterização molecular deste fenótipo já que permite a análise de 
centenas de genes apenas numa população celular. De facto, encontram-se 
disponíveis kits de sequenciação de última geração fornecendo resultados de 
sequenciação fidedignos em rotinas de diagnóstico do cancro, como o Ion Torrent 
Cancer Hotspot Panel v2. Este teste inclui 50 genes conhecidos por estarem 
envolvidos na patogénese de vários cancros humanos. 
Desta forma, o nosso segundo objectivo foi caracterizar células 
CD44+/CD24-/Ck+/CD45- por citometria de fluxo num grupo contendo lesões 
benignas e malignas da mama. O teste Ion Torrent Cancer Hotspot Panel v2 foi 
utilizado para a identificação de mutações somáticas no DNA extraído das células 
CD44+/CD24-/Ck+/CD45- isoladas. A expressão da E-Caderina e da vimentina foi 
também analisada nas lesões malignas.  
A percentagem das células CD44+/CD24-/Ck+/CD45- aumentou 
significativamente a partir das lesões benignas para as malignas e foi 
negativamente correlacionada com o tamanho tumoral. Uma associação 
significativa com a vimentina foi também observada. A partir da análise da 
sequenciação massiva em paralelo, a lesão benigna conteve apenas um 
polimorfismo de nucleótido único. Foram encontradas mutações nos genes TP53, 
NOTCH1, PTEN e AKT1 nas células CD44+/CD24-/Ck+/CD45- isoladas dos 
carcinomas in situ. Mutações adicionais nos genes CSFR1, RET e TP53 foram 
também identificadas nos carcinomas invasores.  
Em conclusão, as células tumorais CD44+/ALDH1+/Ki-67- podem ter um 
maior efeito tumorigénico no cancro da mama do que as células tumorais 
CD44+/CD24-/baixo. Devido à sua função, o ALDH1 pode ser determinante para o 
comportamento das células estaminais cancerosas da mama, para a capacidade 
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destas células em resistirem aos agentes quimioterapêuticos e disseminação para 
outras partes do corpo, a qual pode ser auxiliada pela função do CD44. Mais 
ainda, o estado de quiescência parece ser crucial para a progressão tumoral, para 
a resistência aos agentes quimioterapêuticos e pela propagação metastática das 
células estaminais cancerosas da mama. Estudos posteriores têm ainda de serem 
descritos para inferir sobre a capacidade tumorigénica e metastástica das células 
tumorais CD44+/ALDH1+/alto combinadas com o seu estado de quiescência.      
A caracterização das células CD44+/CD24-/Ck+/CD45- suporta a existência 
de uma capacidade de iniciação tumoral por parte destas células a qual pode ser 
fortalecida pela aquisição de um estado de transição epitélio-mesenquimal. Todos 
os genes mutados que foram detectados neste estudo podem desempenhar 
funções cruciais para o desenvolvimento e transformação das células de mama 
CD44+/CD24-/Ck+/CD45- para um fenótipo maligno, para a manutenção da 
estaminalidade e activação do estado de transição epitélio-mesenquimal. Análises 
funcionais são agora necessárias para determinar os efeitos tumorais de cada 
mutação. Aplicações subsequentes das tecnologias de sequenciação de última 
geração são também necessárias para melhor compreender a progressão 
maligna das células estaminais da mama e para traçar um perfil mutacional 
efectivo destas células.   
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1. Breast Anatomy 
 
The mammary system is very different from other organ systems. From 
birth through puberty, pregnancy, and lactation, the breast is affected by several 
dramatic changes in size, shape and function [1].  
The adult breast lies on the anterior chest wall between the second and 
sixth ribs, and from the sternal edge medially to the mid-axillary line laterally. 
Breast tissue also projects into the axilla as the axillary tail of Spence [2]. 
Anatomically, the breast lies in a space within the superficial fascia, 
although microscopic extensions of glandular parenchyma occasionally traverse 
these boundaries. Superiorly this layer is continuous with the cervical fascia and 
inferiorly with the superficial abdominal fascia of Cooper. Extensions of fibrous 
strands from the dermis into the breast form the suspensory ligaments of Cooper, 
which attach the skin and nipple to the breast [3]. 
An interesting work regarding the anatomy of the nipple suggested the 
existence of more than 20 lobes that are defined by the major lactiferous ducts 
that open on the nipple [4]. A lobe resembles to a tree, whose trunk, branches and 
leaves are hollow. These arborizing networks transport milk from the lobules to the 
nipple and are called the terminal portions of the duct system. One lobule is 
formed by multiple blunt-ending ducts in a cluster like the fingers of a glove. These 
fingers form the glandular acini of the lobule being surrounded by specialized 
connective tissue, histologically different from the stromal connective tissue 
existent in the rest of the breast. The lobule is then formed together by the 
glandular acini and specialized connective tissue. A terminal duct and its lobule 
are collectively called the terminal duct lobular unit (TDLU) which are found as 
immediate branches of the major ducts  [1, 2] (Figure 1). 
The lobular acini are invested by a loose, fibrovascular intralobular stroma 
with different numbers of lymphocytes, plasma cells, macrophages, and mast 
cells. This specialized intralobular stroma is sharply delimited from the surrounding 
denser, more highly colagenized, paucicellular interlobular stroma and stromal 
adipose tissue [5]. 
The number of acini per lobule and the size of mammary lobules have been 
found to be extremely variable. During the menstrual cycle, the morphological 
changes displayed by the lobules are seen in both epithelial and stromal 
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components [6-9]. Although the high variability of such changes that exist among 
lobules in the same breast or even among immediately adjacent lobules, a 
dominant morphologic pattern is typically current in each phase [5]. 
The nipple areola complex is a circular area of skin that exhibits increased 
pigmentation and contains numerous sensory nerve endings. The nipple is placed 
centrally and is prominent above the surrounding areola. Near the periphery of the 
areola are elevations (tubercles of Montgomery) formed by the openings of 
modified sebaceous gland, whose secretion protect the nipple during 
breastfeeding [5, 10]. A keratinizing, stratified squamous epithelium covers both 
the nipple and the areola and extends for a short distance into the terminal 
portions of the lactiferous ducts. During lactation, epithelial cells in both the 
terminal duct and lobule endure secretory changes. Thus, the terminal ducts are 
responsible for both secretion and transport of the secretions to the extra-lobular 
portion of the ductal system [11].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic diagram of the breast. Adapted from [1]. 
 
Cells that form the duct epithelium are of two types: columnar cells, lining 
the lumen having cytoplasm endowed with abundant organelles involved in 
secretion and expressing a variety of low-molecular weight CKs including CKs 7, 
8, 18 and 19 [12-16], and myoepithelial cells being distributed in a discontinuous 
manner in the epithelium [17]. Myoepithelial cells lay between the epithelial layer 
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and the basal lamina forming a network of slender processes investing the 
overlying epithelial cells. These cells range in appearance from barely visible, 
flattened cells with compressed nuclei to prominent epithelioid cells with abundant 
clear cytoplasm. In some cases, the myoepithelial cells have a myoid appearance 
featuring a spindle cell shape and dense, eosinophilic cytoplasm, reminiscent of 
smooth muscle cells. Immunohistochemical stains for several markers are used to 
discriminate these cells, including S-100 protein, actins, calponin, smooth muscle 
myosin heavy chain, p63, and CD10, among others [18-21]. A third cell type in 
normal breast tissue was also recently proposed. These cells were seen to be 
dispersed irregularly throughout the ductal lobular system expressing the basal 
cytokeratin CK5. Due to their ability to differentiate into both glandular epithelial 
and myoepithelial cells, such cells are believed to be progenitor cells [15].  
The epithelial-stromal junction comprises an epithelial-mesenchymal layer 
within the duct, the basal lamina, and a surrounding zone of delimiting fibroblasts 
and capillaries. Elastic tissue fibers are variably present around normal ducts but 
in the premenopausal breast, these fibers tend to be less pronounced. Besides 
elastic fibers, the normal periductal stroma contains a sparse scattering of 
lymphocytes, plasma cells, mast cells, and histiocytes. Ochrocytes are periductal 
histiocytes with cytoplasmic accumulation of lipofuscin pigment. Such pigmented 
cells tend to be more frequent in the post-menopausal breast and are associated 
with inflammatory or proliferative conditions [3].  
Considering that the mature breast is subjected to deep changes 
associated with the menstrual cycle, pregnancy, lactation and menopause, the 
normal microscopic anatomy of the lobules is not constant. Furthermore, and 
regardless of the physiologic conditions, there are variations in the functional state 
of individual lobules suggesting that these individual lobules or lobules in regions 
of the breast may have intrinsic differences in response to hormonal stimuli [22]. 
Due to this intrinsic dynamic ability of breast cells to be continuously influenced 
and remodeled, it is believed that they can be susceptible to carcinogenesis. In 
fact, loss of heterozygosity (LOH) is one of the genetic alterations that have been 
detected in histologically normal-appearing lobular epithelium [23], but other 
genetic changes have also been found in epithelium and myoepithelial cells. 
Although the frequency of these alterations has not been established yet, 
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increasing existing data suggest that they are detected more often in histologically 
normal lobules from patients with carcinoma than in breasts without carcinoma [3].  
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2. Breast Cancer 
 
2.1. Epidemiology 
Breast cancer is a global health problem and one of the major causes of 
female morbidity and mortality [24-26]. Its incidence, prevalence and the economic 
burden it imposes on national health services make it a major public health 
including both the developed and developing countries [27].  
This disease affects women aged less than 45 years being more prevalent 
in the 45-65 years age group. Currently, breast cancer continues to be the leading 
cause of female death from cancer worldwide. In 2012, ~1.67 million new breast 
cancer diagnoses were made throughout the world and 522000 women died of 
breast cancer. In the same year, the incidence in Europe Union Member States 
was ~362000 new cases with 92000 deaths, accounting for a mean incidence rate 
of 66.5 and a mean mortality rate of 16.0 per 100000 women (world age-
standardized rate, ASR-W) [28]. The differences in the incidence, mortality and 
survival rates are due to different risk factors, availability of organized screening 
programs and access to effective treatments [24]. Although the mortality rate is 
higher in less developed countries [29], the incidence of breast cancer in Western 
and Northern Europe is between the highest in the world [28]. For this reason, 
breast cancer prevention continues to be a major public health goal (Figure 2A).  
Portugal applied its first region-based screening program in 1990 but 
nationwide screening was only attained in 2005. The Health Ministry aims at 60% 
coverage by the end of 2016 [30] implementing a program that offers digital 
mammography to women aged 45-69 years. Nonetheless, ~6000 new breast 
cancer cases are diagnosed annually and ~1500 women die due to this disease 
(Figure 2B). Indeed, the incidence rate of 67.6 cases per 100000 people is 
currently higher when compared with the mean established for European Union 
countries. Even if the mortality rates (13.1 cases per 100000 people) are still lower 
than the European ratio, early diagnosis of abnormalities is extremely important to 
better understand the risk of breast cancer progression [28].  
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Figure 2. A. Breast cancer estimated age-standardized incidence and mortality rates in the World 
per 100000. B. Incidence and mortality rates of the most common types of cancer for both sexes in 
Portugal – estimates presented for the year 2012. Adapted from [28]. 
 
2.2. Risk Factors 
In the past several years, significant improvements have occurred in our 
understanding of the causes and prevention of breast cancer. Factors like age, 
family history of breast cancer and experiences of reproductive life have long been 
known to be associated with breast cancer risk [31]. Age is by far the strongest 
risk factor for breast cancer in women. The incidence of this disease increases 
steeply with the greatest rate increment seen in postmenopausal women, where 
the risk doubles with each decade of life up to age 80. Race and ethnicity also 
constitute a marked risk factor, being highest in white women, following by black 
and Hispanic women [32]. Such dissimilarities may be explained by multifactorial 
inherited factors, genetic variations in the biology of the tumors or even cultural 
differences [33, 34]. Reproductive events, such as menarche, pregnancies and 
live births, lactation and menopause, all mark substantial changes that can 
influence breast cancer risk. Incidence may be affected by the effects of physical 
alterations due to reproduction and long-term modifications in hormonal exposures 
[32]. Increasing age at menarche is associated with decreasing breast cancer 
A B
0. 
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incidence; the risk of breast cancer decreases 5% for each year increment in age 
at menarche [35]. Concomitantly, increasing the reproductive span with a late age 
at menopause increases the risk of developing breast cancer due to a greater 
lifetime exposure to circulating hormones [36]. Parity, especially at an early age is 
associated with a decreased risk of breast cancer. Women whose first birth 
occurred at age 35 years or older have a higher risk of developing the disease 
when compared to women under 18 at the time of first pregnancy [35]. In parous 
women, lactation further decreases the risk. Nevertheless, the overall reduction in 
risk varies considerably within the population studied [37].  
Recently, new risk factors have emerged including low physical activity, 
obesity, alcohol intake, and exogenous hormone use. In fact, some of these new 
factors seem to be related to perturbations in circulating estrogens, which are 
believed to be the major cause of breast cancer [31]. Regarding the exogenous 
hormones, studies concerning the use of oral contraceptives and hormonal 
therapy for the menopause are still inconclusive. However, the last is associated 
with increased risk of breast cancer, especially when comparing its use during 
short and long periods of time [38, 39]. 
Women with a family history of breast cancer, particularly in a first-degree 
relative, have approximately double the risk of developing the disease compared 
to women without such a history [40]. Studies of high risk families provided 
evidence of an autosomal dominant inheritance of breast cancer [41, 42]. Gene 
linkage studies and cloning [43, 44] identified two genes, BRCA1 and BRCA2 that 
appear to be associated with the majority of inherited breast cancers accounting 
for 2-5% of all breast cancers [45]. Lifetime risk of diseases associated with 
BRCA1 and BRCA2 mutations ranges from 20 to 80% [46], since that these genes 
are tumor suppressor genes with several important cell functions like transcription, 
regulation of cell cycle checkpoints, genomic stability and DNA repair [47-49].   
Benign breast lesions can also influence risk. Overall, women with benign 
breast lesions without hyperplasia have a 1.5-fold increased risk of breast cancer 
compared to women without any benign breast lesions. The risk between women 
with hyperplasia varies by whether or not atypia is present: women having atypical 
hyperplasia and hyperplasia without atypia have a 2.6-fold and a 1.8-fold 
increased risk, respectively. Women harboring fibroadenomas have an 
independent increased risk for breast cancer [50]. Benign breast disease may be 
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sensitive to the same risk factor as for invasive cancer. Hence, benign lesions 
should be considered as a first step in breast cancer progression [31].    
 
2.3. Prognostic Markers and Therapeutic Strategies in Breast Cancer  
Breast cancer progression evolves through a series of intermediate 
processes, beginning with ductal hyperproliferation, followed by subsequent 
evolution to carcinoma in situ, invasive carcinoma, and finally into metastatic 
disease [51]. Considering the marked heterogeneity of breast cancer, the 
identification of markers that can predict tumor behavior is particularly important. In 
fact, these markers can be seen as a useful tool for the clinical management of 
cancer patients, assisting in diagnostic procedures, staging, evaluation of 
therapeutic response, detection of recurrence, distant metastasis and prognosis 
[52].  
Currently, the standard for assessing the prognosis of patients with newly 
diagnosed stage I-III breast cancer is to use an integrated prognostic model that 
includes information about tumor size, tumor grade, tumor proliferation index, 
lymph node involvement, distant metastasis, estrogen- and progesterone-
receptors (ER and PR) and epidermal growth factor receptor type 2 (HER2) status. 
Such combination and integration converge into a single risk prediction score for 
prognostic stratification [53-55].   
One of the most important prognostic factors is the gross measurement of 
tumor size. Several studies have shown that survival time decreases gradually 
with increasing tumor size. Patients with stage I tumors smaller than 1 cm have a 
20-year disease-free survival (DFS) rate of 88%, whereas patients with tumors 1-2 
cm have a 20-year DFS rate of only 68%. The incidence of lymph node 
metastases is 10% for patients with tumors having 1 cm or less, compared with 
75-80% for patients with tumors larger than 10 cm [56].   
Another important prognostic factor for breast cancer is the presence or 
absence of axillary lymph node metastases and the number of axillary lymph 
nodes with metastatic tumor. Overall survival time, recurrence and time to 
recurrence, metastases and treatment failure, all significantly correlate with the 
number of positive axillary lymph nodes [57-59]. The 10-year DFS rate is around 
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70-80% when axillary lymph nodes are negative for metastatic tumor. With each 
positive node, the OS rate gradually decreases [60]. 
In patients with invasive breast cancer (IBC), histologic grading has been 
constantly shown to predict DFS and OS and is recommended for all invasive 
carcinomas to provide an estimation of differentiation. A histologic grading system 
endorsed by World Health Organization (WHO) and based on criteria established 
by Bloom and Richardson and Eslton and Ellis evaluates three parameters: tubule 
formation, degree of nuclear pleomorphism and number of mitotic figures identified 
on histologic sections. Elston and Ellis found that patients with grade 1 tumors had 
a significantly better OS than those with grade 2 or grade 3 tumors [61].  
In respect to breast cancer treatment, all cancer therapy can be divided into 
two basic types: local and systemic therapy. Local therapy refers to those 
treatments that control disease in the specific area of the tumor. Surgery to 
remove the breast mass is one of the first treatment methods but the extent of 
surgery depends on the features of a specific tumor. Even if a mastectomy may be 
mandatory for some patients, in several cases, only a small portion of the breast at 
the tumor site is removed. Surgery may be followed by radiotherapy in order to kill 
any cancer cells that may remain after surgery. In fact, clinical studies have shown 
that for the majority of breast cancers, removal of the breast lump followed by 
radiotherapy is as effective as surgery to remove the whole breast [62].     
After the surgery and before radiation begins, it is important to discuss the 
role of systemic adjuvant therapy that includes endocrine therapy, chemotherapy, 
and/or targeted therapy. After examining the risks versus the benefits of the 
therapy, the use of such therapy is recommended or not. The benefit of adjuvant 
or endocrine therapy is in proportion to the risk of breast cancer recurrence; 
however, and despite the existence of prognostic factors, no parameter is 
completely predictive of recurrence [63, 64]. The majority of the clinicians agree 
that many women with node-negative breast cancer should receive adjuvant 
chemotherapy, especially those with larger tumors. Women with tumors smaller 
than 1 cm, a low-grade malignancy, positive ER/PRs, negative HER2 status and a 
low proliferative rate have the lowest risk of recurrence. Conversely, women with 
tumors larger than 2 cm, a high-grade malignancy, negative ER/PRs, positive 
HER2 status, triple negative receptor status (ER, PR and HER2 negative) and a 
high rate of proliferation are at highest risk for tumor recurrence [63]. Currently, 
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ER, PR and HER2 scores have been used along with the Ki-67 proliferation 
marker as predictive factors for identifying a high-risk phenotype and also for the 
selection of the most efficient therapies [65].  
 
- Ki-67  
Ki-67 is a nuclear protein expressed in all phases of the cell cycle other 
than the G0 phase and is used to assess proliferation in breast cancer. A high 
percentage of Ki-67-positive cells are associated with poor prognosis and the 
optimal cutoff between high and low risk of developing distant metastasis has 
been suggested to be 14% of positive cells [66]. 
The analysis of the value of Ki-67 as a predictive and prognostic tool is 
useful for neoadjuvant setting. Some studies examining complete pathological 
response have identified a high Ki-67 proliferation rate as a predictive factor for a 
higher rate of complete pathological response. It was found however, that patients 
in whom progression occurred had a higher proliferation rate than those who 
responded to neoadjuvant chemotherapy. These results suggest a nonlinear effect 
of Ki-67 on treatment response and probably on prognosis as well [67, 68]. 
Nonetheless, proliferation as assessed by the percentage of Ki-67 positive cells 
combined with ER, PR and HER2 scores has a strong prognostic power especially 
in patients with ER-positive breast cancers. 
 
- Hormonal Receptors 
The clinical significance of ER and PR status in IBC has been well 
recognized for decades and the measurement of ER and PR levels became a 
standard practice when evaluating patients with primary breast cancer [69-74]. 
ERs and PRs belong to a super family of nuclear hormone receptors that 
function as transcription factors when they are bound to their respective ligands 
[75, 76]. These receptor proteins are generally divided into six functional regions. 
The ligand-binding now called ERα contains an amino-terminal, hormone-
independent activation function (AF-1) domain, a centrally located DNA-binding 
domain followed by a hinge region, the hormone-binding domain with its integral 
hormone-dependent region (AF-2) and a carboxyl-terminal F domain. Binding of 
hormone to ERα triggers the activation of the receptor leading to the 
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disassociation of receptor coregulatory repressor proteins and histone deacetylase 
complexes. Conversely, the recruitment of several coactivator protein complexes 
with histone acetylase activity acts in coordination to induce the transcription of 
estrogen-responsive genes. ERβ contains a similar structure, encoding however a 
smaller AF-1 domain as well as the PR-A and PR-B isoforms which also differ 
predominantly in their amino-terminal regions [77]. The detailed structure-function 
studies of AF-1 and AF-2 regions were fundamental insights into a molecular basis 
for hormone receptors due to the demonstration of different activities contained 
within these two regions [78]. It was shown that in a cell where AF-2 domain is 
dominant, antiestrogens such as tamoxifen act as pure antagonists. However, in a 
cell where AF-1 domain is dominant, tamoxifen behave as a partial agonist 
stimulating ERα transcriptional activity and proliferation [79, 80]. This modulation is 
the reason why different antiestrogens like tamoxifen or raloxifene are also termed 
selective ER modulators or SERMs: they can function as antagonists in the breast, 
but also as ERα agonists in other tissues, like the bone and cardiovascular 
systems [78].   
Although the majority of studies suggest that like ERα, ERβ protein 
expression is also associated with a better outcome in untreated patients with 
breast cancer, the prognostic value of ERβ still need to be depicted. When 
tamoxifen binds to ERα, the estrogen-stimulated growth of tumor cells is inhibited 
leading to a significant reduction of cancer recurrences and to an increment in 
survival in patients with ERα positive IBCs of all stages [81]. More recently, 
tamoxifen has also been shown to reduce subsequent breast cancer in patients 
with ERα positive DCIS [82] and in patients who are cancer-free but at high risk for 
developing breast cancer [83]. ERα loss as a significant mechanism of acquired 
hormonal resistance is still an important question to be solved because even if 
ERα is reduced in tamoxifen-resistant tumors, the development of hormonal 
resistance is more frequently associated with the maintenance of ERα at the time 
of progression [84]. For this reason, the clinical use of other endocrine agents with 
distinct mechanisms of action, such as the steroidal antagonist faslodex has 
emerged. Currently, about two-thirds of tamoxifen-resistant breast cancer patients 
respond to second-line therapy with faslodex, exhibiting no ERα agonist activity in 
cells [85]. Additionally, a third generation of anastrozole and letrozole was shown 
to be effective in postmenopausal tamoxifen-resistant patients [86]. Thus, 
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tamoxifen cannot be assumed as a global hormonal resistance antagonist, 
suggesting a multiple mechanism of hormonal resistance and involving a 
combined pool of SERMs.  
 
- HER2 
The HER2 gene (also known as c-ErbB2) encodes a 185-kDa 
transmembrane tyrosine kinase receptor [87] belonging to the epidermal growth 
factor receptor (EGFR) family. Such family also includes HER1, HER3, and HER4. 
These receptors are sensitive to signals that stimulate cell growth being expressed 
in a variety of tissues of epithelial, mesenchymal, and neuronal origin [87]. The 
homo- and heterodimerization with one another allows the auto-phosphorylation of 
tyrosine molecules, and consequently, the propagation of intracellular signaling 
through the mitogen-activated protein kinases (HER1/HER2 heterodimers) and 
phosphoinositide 3-kinase (PI3K) pathways (HER2/HER3 heterodimers). HER2 is 
unique due to its ability to dimerize with any of the other three receptors and 
besides that, it does not require ligand binding for activation [88].  
This oncogene is amplified in 20 to 30% of breast cancers and since that its 
overexpression is associated with an aggressive phenotype of tumor cells, 
resistance to antihormonal and cytotoxic therapies and poor OS, it is considered 
as a marker of poor prognosis [52]. Currently, the humanized monoclonal antibody 
trastuzumab targets the extracellular domains of HER2 being thus indicated for the 
treatment of HER2-positive breast cancers. Several studies demonstrated the high 
efficacy of trastuzumab through its significant inhibitory effect on tumor growth and 
chemotherapy sensitizer [89]. Such anti-tumor effect is believed to be conferred by 
the inhibition of receptor-receptor interaction, receptor decreasing by endocytosis, 
blockade of extracellular domain cleavage of the receptor and activation of 
antibody-dependent cellular cytotoxicity [90, 91]. Besides trastuzumab, other 
therapeutic strategies have been designed to target HER2 protein such as 
lapatinib, a tyrosine kinase inhibitor which showed enhanced efficacy after failure 
of trastuzumab therapy [92]. 
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2.4. Molecular Subtyping of Breast Cancer 
 Although heterogeneity in breast cancer has long been recognized, recent 
microarray-based gene expression profiling analysis [93, 94] brought this concept 
to the vanguard of breast cancer research.  
Studies published by Perou et al and Sorlie et al have demonstrated that 
breast carcinomas can be classified according to the similarity between their 
transcriptomic profiles. For instance, the authors developed an “intrinsic gene set” 
(i.e genetic differences between samples from different patients and samples from 
the same patient) and through hierarchical clustering analysis, tumors were 
classified into four main groups: (A) luminal, comprising ER-positive tumors and 
expressing genes belonging to the ER pathway with profiles corresponding to 
“normal luminal epithelial cells”; (B) basal-like cancers, which are hormone 
receptor negative/low tumors expressing genes that are usually expressed by 
basal/myoepithelial cells; (C) HER2 tumors with HER2 overexpression and genes 
belonging to the HER2 amplicon, and (D) normal breast-like group, which clusters 
together with normal breast samples and fibroadenomas [95, 96]. 
However, the molecular taxonomy of breast cancer is constantly being 
modified since that in each publication different intrinsic gene lists are 
demonstrated. As a consequence, slightly different subtypes have emerged like an 
interferon-rich group [97], the molecular apocrine subtype [98, 99] and the claudin-
low subtype [100] (table 1). 
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Table 1. Characteristics of molecular subtypes of IBCs. Adapted from [101]. 
 
Molecular subtype ER PR HER2 Basal 
markers 
Proliferation Histology 
Luminal A +++ +++ - - Low 
Low grade ductal, 
cribiform, tubular, 
classic lobular 
Luminal B + ± ± ± High Ductal , micropapillary 
HER2-enriched +/- +/- + ± High High-grade ductal 
Basal-like - - - + High High-grade ductal, 
metaplastic, medullary, 
adenoid-cystic 
Molecular 
apocrine 
- - ± ± High Apocrine, ductal, 
lobular 
Claudin-low - - - ± High High-grade ductal, 
metaplastic 
+++ High expression, + moderate expression, ± variable expression, - no expression  
ER-positive expression markedly defines the luminal molecular subtype, 
which is also characterized by the relatively high expression of several genes 
expressed by breast luminal cells like CK8/18, GATA3 and estrogen-regulated 
genes. Luminal tumors are divided into luminal A and luminal B tumors due to their 
different ERα expression levels, proliferation rates assessed by Ki-67 and clinical 
outcomes [102]. However, patients with luminal tumors have better outcomes and 
a broader range of treatment options than patients with other types of breast 
cancer [103]. 
The overexpression of the HER2 protein on the cell membranes is due to 
the genomic amplification of the 17q22.24 region, which constitute the HER2-
enriched molecular subtype. HER2-enriched tumors can be ER-positive and/or 
PR-positive and have a more aggressive phenotype than HER2 normal tumors. 
Still, overexpression of HER2 makes the majority of these tumors highly 
responsive to HER2 inhibitors such as trastuzumab [104]. Intrinsically, ER-
positive, HER2-enriched tumors have a poorer response to systemic therapy than 
ER-negative, HER2-enriched tumors [103]. 
Basal-like breast cancers have the worst clinical outcome when compared 
with all others breast cancer groups. They are characterized by an aggressive 
phenotype with high histologic grade, high proliferation levels pushing borders of 
Chapter 1. General Introduction 
 
17 
 
invasion and large areas of tumor necrosis, representing 15-20% of breast 
cancers [105]. Such tumors express high levels of basal-markers like CKs 5, 14 
and 17 but do not express ERα, PR or HER2. Consequently, anti-hormonal 
approaches for these tumors are unfeasible and also, the poor genetic knowledge 
regarding the transformation and progression of this tumor subtype makes it 
difficult to target with current therapies [106].   
Accounting for 8-14% of breast cancers, the molecular apocrine subgroup 
was shown to be distinct from luminal and basal-like breast cancers. It is 
characterized by increase androgen signaling and is frequently associated with 
apocrine histological features. This molecular phenotype is thought to be 
associated with poor long-term survival and has specific surrogate 
immunohistochemical markers, including androgen receptor- and gamma-
glutamyltransferase 1 [103, 107].  
Claudin-low tumors account for approximately 5% of IBCs and are 
characterized by low or absent expression of EMT markers, presence of immune 
response genes and cancer stem cell-like features [108]. Clinically, the majority of 
claudin-low tumors carry poor prognosis and are ER-negative, PR-negative and 
HER2-negative (triple-negative) tumors that have a higher frequency displaying 
metaplastic and medullary differentiation [109]. 
It should be noted however, that this molecular taxonomy, as referred 
above, remains a working model in progress and not a definitive classification 
system, as additional molecular subtypes have been and may be identified in the 
future. 
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3. Breast Tumorigenesis 
 
As previously discussed, the normal microscopic anatomy of the lobules in 
a mature breast is not constant and such fluctuation strongly influence how breast 
cells respond to a certain hormonal stimuli [22]. Such influence can render these 
cells susceptible to carcinogenesis. Considering that high responses to hormonal 
stimulus occur at the level of TDLUs, many of the known epithelial benign and 
malignant lesions arise from these terminal units.    
 
3.1. Benign Lesions 
Benign breast disease can be classified into non-proliferative, proliferative, 
atypical hyperplastic and miscellaneous lesions. Such categories are defined 
depending on the degree of atypia and cellular proliferation of a lesion as well as 
its susceptibility for developing into breast cancer [110]. Although the pathway 
from normal terminal ductal lobule to premalignant breast lesions, noninvasive and 
invasive cancer has been well defined morphologically, the major cause of benign 
breast diseases remains unknown [111]. Non-proliferative lesions are common 
and almost never increase the risk of developing breast cancer, while proliferative 
lesions without atypia are the most common type of benign breast lesions being 
associated with a small increase in breast cancer risk. Conversely, atypical 
hyperplasia is associated with a moderate to high risk to evolve into breast cancer 
[110].  
The frequency of benign lesions is particularly variable with age. 
Fibroadenoma is frequent in younger patients while other localized benign and 
cysts occur most frequently in women between the ages of 30 and 50 [112]. The 
cumulative incidence of such diseases is approximately 10–20%, although 
autopsy studies have reported a much higher prevalence, at approximately 50% 
[113]. Whether some of the conditions of benign lesions (such as proliferative 
disease with atypia) are direct precursors to premalignant and invasive 
malignancy, as hypothesized by the modified Wellings Jensen model remains 
unclear [114]. In this way, investigation of management strategies is still needed to 
infer about which patients could potentially benefit from closer adherence to 
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existing screening recommendations, from additional screening modalities or even 
from chemoprevention [115]. 
 
3.2. In situ Breast Carcinomas 
In situ breast carcinomas are a group of malignant lesions that can be 
confined inside the ducts (DCIS) or lobules (lobular carcinoma in situ or LCIS) of 
the breast. Such classification was previously based on the similarity of the 
involved spaces to normal ducts or lobules. Nonetheless, it is now well established 
that different patterns of in situ growths mainly reflect differences in tumor cell 
biology rather than being associated to the site or cell of origin. Presently, “lobular” 
refers to carcinomas of a specific type and “ductal” is more generally used for 
adenocarcinomas that have no other designation [116]. While LCIS is a rare 
lesion, DCIS currently account for 20-25% of all newly diagnosed breast cancer 
[117]. DCIS is defined as a premalignant proliferation of neoplastic epithelial cells 
contained within the lumen of mammary ducts. These carcinomas are lined by a 
layer of semi-continuous myoepithelial cells and surrounded by an intact basement 
membrane [118]. 
The risk of DCIS is rare in women younger than 30 years, is low in women 
younger than 40 years, but increases steadily from age 40 to 50 years. After that, 
the risk increases much more slowly and plateaus after 60 years of age. As a 
generalized risk factor, DCIS has an approximately 8- to 10-fold increased risk for 
subsequent invasive cancer [119]. 
 There is no universally accepted histopathological classification for DCIS, 
but the majority of pathologists traditionally divide these carcinomas into five major 
architectural subtypes (papillary, micro-papillary, cribiform, solid and comedo), 
often discriminating the first four (non-comedo), from comedo [120-122]. The 
concept of nuclear grading has also assumed greater importance and significance 
in classification of DCIS lesions (low versus intermediate versus high). Actually, 
nuclear grade is considered to be a better biological predictor than architecture 
and has emerged as key histopathological factor for identifying aggressive 
behavior [123-125]. Comedo DCIS for example, is frequently associated with a 
higher nuclear grade aneuploidy, a higher proliferation rate, HER2 amplification or 
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protein overexpression, and clinically more aggressive behavior in opposition to 
non-comedo lesions [120-122, 126-128]. 
There are strong correlations between histological differentiation in DCIS 
and prognostic biomarkers in breast cancer. For example, almost all well 
differentiated or low-grade DCIS express high levels of ERα and PR in nearly all 
cells [129-131]. In the majority of poorly differentiated lesions, the proportion of 
cases expressing these receptors gradually decays to about 20% as well as the 
average proportion of positive cells [132]. Conversely, overexpression and 
amplification of HER2 and inactivating mutations of p53 are rare (5-10%) in well 
differentiated DCIS, but in the most poorly differentiated lesions, such alterations 
gradually increase to about 60% [130, 133-136]. 
Moreover and from lowest to highest grade, the average proliferation 
gradually increases from <5% to nearly 40% respectively and apoptosis varies in 
the same direction from <1% to over 5% [120, 137, 138].  
Although there have been several efforts towards an improvement of clinical 
or molecular tests [139] to predict which patients are likely to develop invasive 
disease following a diagnosis of DCIS, currently, no test is clinically useful to 
identify this population. As a consequence, the vast majority of patients are still 
subjected to surgical treatment (breast reduction/total mastectomy) followed by 
radiation and/or prophylactic systemic therapies (e.g. tamoxifen) [140]. 
 
3.3. Invasive Breast Carcinoma 
By definition, invasive breast tumors invade adjacent benign breast 
parenchyma and are capable of metastasis to distant sites. Classification of IBC 
falls into two broad subtypes: ductal and lobular carcinoma. Beyond these 
subtypes, several histologic patterns or phenotypes have a tendency to behave 
similarly and for that reason, such patterns are of great importance to clinicians 
[141]. 
Invasive ductal carcinoma not otherwise specified (IDC-NOS), comprises 
the largest subgroup of IBCs, accounting for 40-75% of all invasive breast tumors. 
The histological appearance of IDC is variable between individual tumors since 
that tumor cells may infiltrate as well-formed tubules, cords, clusters, or they may 
be arranged in solid sheets [141].  
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In IBCs, a strong correlation is markedly seen between tumor size and the 
incidence of axillary lymph node metastases and survival rates [61, 142, 143]. 
Characterization of such IBCs is best defined by grade and phenotype and by the 
most common immunohistochemical profile that is, a tumor positive for ER (60-
70% of cases) and negative for HER2 (75-85% of cases) [141].  
The majority of the special types of IBCs display relatively good prognosis 
and have an ER-positive and HER2-negative phenotype including ILC and tubular, 
cribiform, muscinous and papillary variants of IDC. The identification of such types 
of IBC is of great importance and in conjunction with other major prognostic 
factors, the prediction of likely behavior and response to treatment can be 
significantly improved [144]. Therefore and upon the retrieve of all relevant 
information together with patient age and overall health status, a treatment course 
can then be discussed. Adjuvant versus neoadjuvant therapy and breast 
conservation versus mastectomy remain the major decisions at the beginning of 
breast cancer treatment. After the appropriate treatment, almost all breast cancer 
patients are clinically free of disease. However, some of these initially cured 
patients will have a systemic treatment failure over the course of 5–10 years. The 
rates of such treatment failure vary between 5% up to 50%, depending on 
prognostic factors [145]. 
In patients treated with adjuvant chemotherapy, several prospective studies 
showed a measurable decrease in long-term systemic failure and mortality 
between 10% and 20%. Nonetheless and until now, it has been impossible to 
precisely determine which patient will benefit from this treatment culminating in an 
overtreatment of thousands of patients worldwide. Such limitation leads to an 
interesting pursuit for genetic tumor profiles benefiting from chemotherapy and 
profiles already cured by local therapy [145]. 
Several chemotherapeutic procedures have been developed over the years 
starting with the cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) 
regimen [146]. The introduction of targeted therapy as another major oncologic 
breakthrough specific for the treatment of breast cancer allowed the use of 
antiestrogens such as tamoxifen and fulvestrant and, later, aromatase inhibitors. 
Indeed, adjuvant treatment with antihormonal medication has proven to be 
successful for more than 60% of patients (which are positive for ER and PR) [147]. 
An additional targeted therapy was introduced for those 15% of breast cancer 
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patients positive for HER2 which in fact turned to be extremely effective. With the 
implementation of trastuzumab, other substances such as lapatinib, pertuzumab, 
and trastuzumab-emtansine were shown to be also effective in treatment of HER2-
positive breast cancers [145]. 
In advanced health systems, 80−85% of breast cancer patients will be 
cured. Due to long-term relapse, follow-up became a major issue since that 
patients with previous breast cancer are at high risk of recurrences. At the same 
time, breast cancer survivors are breast cancer advocates since they show how 
this increasingly common disease can be cured. The decline in breast cancer 
mortality has been attributed to the combination of early detection with screening 
programs as well as the existence of more effective adjuvant systemic therapy. 
Improvements in our understanding of the molecular biology of breast cancer 
progression allowed the discovery of novel pathway-specific targeted therapeutics. 
Indeed, the continuous development of such effective therapeutics is currently 
demanding for a molecular-based, ‘patient-tailored’ treatment planning through 
continuous studies of the molecular pathology of human breast cancer progression 
[148]. 
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4. Breast Cancer Progression 
 
4.1. Theories of Breast cancer Progression 
The first classifications for pre-invasive lesions were based on the site or 
cell of origin giving rise to different names of in situ proliferation like DCIS or LCIS. 
However, the demonstrations done by Wellings et al regarding the origin of such 
pre-invasive lesions in the TDLUs constituted a paradigm shift of the histogenetic 
implications of the ductal and lobular terminology, marking the beginning of 
epidemiological and morphological observations [111, 149, 155]. Such 
observations led to the formulation of various linear models of breast cancer 
initiation, transformation and progression (Figure 3). 
Figure 3. Historical model of breast cancer development and evolution based on morphological 
features and epidemiological studies. A. Classic model of breast cancer progression of the ductal 
type; B. Alternative model of breast ductal cancer progression; C. Model of lobular neoplasia. 
Abbreviations: ADH, atypical ductal hyperplasia; ALH, atypical lobular hyperplasia; DCIS, ductal 
carcinoma in situ; LCIS, lobular carcinoma in situ; FEA, flat epithelial atypia; IDC, invasive ductal 
carcinoma; ILC, invasive lobular carcinoma; UDH, usual epithelial ductal hyperplasia. Adapted from 
[118, 148]. 
Indeed, the continuous work of Wellings and colleagues culminated in a 
breast cancer progression model, where for the ductal subtype, flat epithelial 
atypia (FEA), atypical ductal hyperplasia (ADH) and DCIS were the non-obligate 
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precursors of invasive and metastatic ductal carcinoma (Figure 3A) [149-153]. A 
second “ductal subtype” model proposed by Page and Dupont through 
epidemiological studies postulated that usual epithelial ductal hyperplasia (UDH) 
was an intermediate stage of progression between FEA and DCIS (Figure 3B) 
[154, 155]. This second model was posteriorly disbelieved due to 
immunohistochemical and molecular biological evidences against UDH as an 
intermediate stage of progression [156-158]. Regarding the lobular subtype, the 
progression scheme recognizes atypical lobular hyperplasia (ALH) and LCIS as 
the non-obligate precursor lesions of ILC [159, 160] (Figure 3C). 
With the continuous improvements of genetic-based technologies, 
chromosomal (CGH) and microarray-based comparative genomic hybridization 
(aCGH) and microarray-based expression profiling studies [161] have deeply 
changed the perspective of breast cancer progression: low-grade IDCs were 
shown to display fewer overall chromosomal aberrations as compared with high-
grade IDCs [162-164]. In fact, recurrent chromosomal loss of 16q and gains of 
1q,16p and 8q observed in low-grade tumors IDCs and the recurrent losses of 8p, 
11q, 13q, 1p and 18q and gains of 8q, 17q, 20q and 16p observed in high-grade 
tumors suggested a different breast cancer progression model than previously 
proposed [163, 164]. The absence of 16q deletions in the majority of high-grade 
breast cancers and expression profiling analysis of matched in situ and invasive 
breast lesions led to the assumption that lesions would cluster according to their 
histological grade rather than stage of progression [165, 166]. In this way, a low- 
and high-grade multistep model of breast cancer progression based on 
morphological, immunophenotipical and molecular features was proposed (Figure 
4). The low-grade group comprises lesions that present molecular characteristics 
such as expression of hormone receptors, lack of HER2 overexpression and 
expression of basal markers, containing simple, diploid/near diploid karyotypes 
with recurrent changes like the deletion of 16q (>80%) and gains of 1q (>75%) and 
16p (>50%) [118].      
The high-grade group comprises microglandular adenosis (MGA) lesions, 
high-grade DCIS and high-grade invasive carcinomas. This group, contrarily to the 
low-grade group is more heterogeneous comprehending lesions classified by 
microarray expression profiling as luminal B, HER2-enriched, basal-like, claudin-
low and molecular apocrine [93, 167]. At the molecular level, high-grade 
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carcinomas display losses of 1p (60%), 8p (60%) and 17p (60%) and gains of 1q 
(60%) and 8q (75%). Amplifications are commonly observed in the high-grade 
lesions, occurring most frequently at 1q, 8q, 17q and 20q chromosome arms [168]. 
As described above, the most notorious difference between the two groups rely on 
the deletion of 16q chromosome arm, which in the high-grade group is seen in less 
than 30% of cases [151, 163, 164, 169, 170].  
 
Figure 4. Low- and high-grade multistep model of breast cancer progression based on 
morphological, immunophenotypical and molecular features. Solid arrows represent links between 
morphological entities demonstrated by morphological and/or molecular data. Dotted arrows 
represent hypothetical links still needed to be demonstrated. Abbreviations: ADH, atypical ductal 
hyperplasia; APH, atypical apocrine hyperplasia; CCH, columnar cell hyperplasia; CCL, columnar 
cell lesion; DCIS, ductal carcinoma in situ; E-cad, E-cadherin; FEA, flat epithelial atypia, IDC: 
invasive ductal carcinoma; ILC, invasive lobular carcinoma; LN, lobular neoplasia; MGA: 
microglandular adenosis; PLCIS, pleomorphic lobular carcinoma in situ. Adapted from [118].    
 
Even with this well characterized breast cancer progression model 
supported and confirmed by genome-wide profiling studies, recent outcomes 
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suggested that breast cancers can be also clustered in two main groups, 
depending on the expression of ER and ER-regulated genes. Such clustering 
highlights the importance of the ER pathway as having a determinant role in breast 
cancer progression, supported by the associations seen between the patterns and 
regions of genomic amplification with the ER status of a given lesion [171, 172]. 
Nonetheless, even with the notion that ER-positive and ER-negative breast 
cancers are fundamentally different diseases, marked evidences strongly support 
that genetic instability displayed by a given lesion is related to its histological grade 
[173, 174].   
 
4.2. Transition from DCIS to IBC 
For several decades it has been accepted that DCIS constitutes a non-
obligate precursor of IBC. Since the demonstration of the breast cancer 
progression model by Wellings and Jensen that a plethora of succeeding work 
aimed to characterize DCIS and IBCs at the molecular level, which have shown 
their genetic similarity and likely common origin [164, 170, 175, 176]. Further 
studies supported the hypothesis that DCIS is a precursor of IBC, mainly due to 
the clinical observation that these lesions affect the same anatomical site, 
representing thus progressive stages of an evolutionary scale. Indeed, and at the 
time of diagnosis, DCIS is frequently found adjacent to the majority of IBCs so 
such coexistence would support the notion of DCIS as the precursor lesion [177, 
178]. Nonetheless, this coexistence varies according to the subtype of breast 
cancer [179].  
Regarding the different molecular subtypes, DCIS can also be classified like 
IBCs are, through the expression patterns of ER, PR, HER2, EGFR and CKs 5/6 
[180-185]. Interestingly, associations of in situ and invasive components were 
shown to not always display a similar immunophenotype: in some HER2-positive 
tumors, HER2 amplification was found to be present in the DCIS but not in the 
associated IBC and even within the DCIS component, an evident heterogeneity of 
HER2 overexpression was seen [175, 184-187]. Explanations for such data rely on 
two different interpretations: loss of HER2 amplification during progression to IBC 
or; a clone from the DCIS component not harboring HER2 amplification gave rise 
to the IBC component [140]. The recent evidences for a convergent phenotypic 
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evolution in tumor progression and metastasis can be applied to explain the 
progression from DCIS to IBC, which actually can be regarded as a possible 
explanation for the negative results in the genomic and transcriptomic 
comparisons between these two lesions [188] (Figure 5A).              
The theories of progression from DCIS to IDC can be divided in two major 
hypotheses: the first one is based on the occurrence of genetic aberrations in 
neoplastic cells as the cause of invasiveness, and the second one suggests that 
tumor progression is not due to additional genetic changes within the lesion but 
rather due to the microenvironment or tumor stroma. Gene expression profiling 
evidences supported this last idea through the demonstration of substantial 
changes in several cell types of the tumor microenvironment (e.g, fibroblasts, 
myoepithelial cells and leukocytes) during progression from DCIS to IBC [140, 
189-191]. However, with the lack of a clear cause for this difference in gene 
expression and with the expected absence of clonal genetic aberrations in these 
cell types surrounding DCIS and IBC, epigenetic alterations in the stroma emerged 
as a complementary explanation for tumor progression [192]. One of the major 
histological characteristic of DCIS lesion is the presence of an outer layer of 
myoepithelial cells and an intact basement membrane. Looking at the theories of 
tumor progression, it was obviously acceptable to assume that this layer of 
myoepithelial cells were responsible to exert tumor suppressive effects on the in 
situ lesion, but the loss of such ability would in turn trigger invasion through the 
release of tumor cells [193-196]. Indeed, myoepithelial cells were shown to secrete 
several extra-cellular matrix (ECM) components and protease inhibitors such as 
Maspin, further proposed to inhibit the invasive capacity of DCIS in a paracrine 
manner [193, 197, 198]. Epigenetic changes have also emerged as an explanation 
for the lack of significant differences detected between DCIS and IBC at DNA 
sequence level. However, even if DNA methylation was seen to be higher in DCIS 
lesions when compared with the normal breast epithelium, similar levels of 
promoter hypermethylation in DCIS and IBC were detected in the majority of 
studies done so far [199-201]. Consequently, such findings explain early events in 
breast carcinogenesis rather than later events for the transition to an invasive 
disease. Alternative epigenetic changes other than methylation were proved to be 
more important in the progression from in situ to IBCs. EMT for example, regulated 
by global changes in histone modifications that mark heterochromatin and 
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euchromatin was reported to be associated with progression from DCIS to IBC 
[202, 203]. As a consequence, additional epigenetic studies still need to be done 
concerning the progression of breast tumors. 
Another concern in breast cancer progression is to determine both intra-
tumor genetic heterogeneity in both components of DCIS and IBC and also the 
genetic differences acquired during progression to IBC. Recent studies have 
shown a wide genetic heterogeneity regarding the number of DCIS tumor cells 
harboring amplification of specific loci. Interestingly, these tumor cells also 
presented some evidence suggesting a clonal selection during the progression to 
an invasive state. In other words, the transition from DCIS to IBC can be regarded 
as an evolutionary bottleneck, following a Darwinian evolution [204-207] (Figure 
5B). Consequently, the employment of MPS and single cell analyses is an 
important next step to discern the contribution of genomic alterations and 
Darwinian evolution to the transition from DCIS to IBC.  
 
Figure 5. Hypothetical models of progression from in situ to invasive breast cancer. A. Progression 
from DCIS to IDC as a convergent phenotype. B. Progression from DCIS to IDC as an evolutionary 
bottleneck. Abbreviations: DCIS, ductal carcinoma in situ; IBC, invasive breast carcinoma. Adapted 
from [140]. 
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4.3. Breast Cancer Progression and Next-Generation Sequencing 
In recent years, whole-genome sequencing has become a powerful tool to 
dissect the evolutionary history of a cancer. Analogous to species comparisons, an 
evolutionary lineage three based on somatic genomes from a single individual can 
be delineated, giving essential insights on somatic evolution studies, even with the 
low rate of mutations in normal tissues [208]. With such improvements, it is now 
possible to detect the genomic changes during tumor evolution by comparing the 
genome of a cancer to clinically precursor lesions. Considering the frequent 
associations of early neoplastic breast lesions with advanced breast cancers, this 
type of cancer became the most suitable for whole-genomic sequencing studies 
providing windows into the earliest stages of tumor evolution [118, 148, 160, 179]. 
With the introduction of NGS by sequencing both the tumor and the 
germline DNA, somatic genetic changes can be classified in two major ways: 
driver or passenger mutations. By definition, driver mutations are those that give 
survival advantages to tumor cells due to the tumor microenvironment changes 
contributing thus for tumor development, while passenger mutations are the 
product of the genomic instability of the tumor [208, 209]. However, the distinction 
between driver and passenger mutations can change during the carcinogenesis: 
looking at the Darwinian evolution, a passenger mutation can become a driver 
mutation after therapy or changes in nutritional or immune status of a tumor 
leading to resistant clones that will prevail and progress along the tumorigenesis. 
Another classification of mutations is also related to the type of genetic 
alteration: nucleotide substitution mutations, small insertions and deletions (also 
called “indels”), copy number gains and losses, chromosomal rearrangements as 
well as nucleic acids from foreign origin [210]. Analysis of the molecular features of 
early stage breast cancer using NGS has led to a genomic landscape portrait of 
this disease: TP53 and PIK3CA mutations were demonstrated to be the most 
frequent genomic alterations in all breast cancer subtypes (28% for both genes), 
while amplifications in ERBB2, FGFR1 and CCND1 were observed in 10-20%. 
Clinical relevance of PTEN mutations and deletions as well as AKT1, RB1, BRCA1 
or BRCA2 mutations was reported and subsequent sequencing analysis of 
mutations in other genes like KRAS, APC, NF1, SKT11, MAP2K4, MAP3K1 and 
AKT2 were also shown to have some clinical relevance [211]. Moreover, and 
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within the breast cancer subtypes, a marked heterogeneity regarding the 
molecular alterations was also reported in triple-negative breast cancers [212].  
At the RNA level, a study involving the comparison of RNA sequencing with 
the genomes/exomes has revealed that only 36% of validated somatic single 
nucleotide variants (SNVs) were observed in a transcriptome sequence, which has 
questioned the use of NGS alone to identify potential drivers of breast cancer 
[212]. Regarding the proteomic analyses in early stage breast cancer, three 
pathways were reported to be predominantly activated in all subtypes: 
PI3K/AKT/mTOR, p53 and CCND1/CDK4/Rb [211]. 
In the near future, NGS will allow the development of catalogues of cancer-
related genes as well as the identification of driver mutations that are responsible 
for tumor development. The characterization of the genomic landscape of tumors 
and of the activated protein networks will guide combination therapies to optimize 
therapeutic effects. In fact, such technologies are being directed for a personalized 
medicine improving considerably the management of patients [213].   
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5. Theories of cancer evolution 
 
Breast cancer heterogeneity is now largely established and categorized by 
tumor segregation into distinct molecular subtypes defined by gene expression 
profiles that correlate with clinical behavior [214, 215]. Despite such 
improvements, the existence of tumor heterogeneity still has to be fully elucidated. 
The two major theories that explain the existence and maintenance of tumor 
heterogeneity are the CSC hypothesis and the clonal evolution model. These two 
models, initially thought to be mutually exclusive, are now currently believed to be 
the complement of each other [216, 217]. Actually, both hypotheses support the 
notion that tumors arise from single cells affected by several molecular alterations 
and developing unlimited proliferative potential. Moreover, both models also rely 
on the microenvironmental features that shape the composition of a cancer; 
nonetheless, these two concepts have important differences (Table 2). The clonal 
evolution model is not based on a hierarchical model but explains intra-tumor 
diversity by natural selection instead, where tumor progression and resistance to 
therapy follow the Darwinian guidelines. Consequently, the emergence of resistant 
clones that progress along the tumorigenesis depend on the genetic instability and 
microenvironment and/or different selective pressures. In turn, the CSC hypothesis 
assumes the existence of a hierarchical organization of cancer cells where only a 
small fraction of cells are able to drive tumor progression and are inherently 
therapy-resistant [206].   
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Table 2. Tenets of the clonal evolution and cancer stem cell models. Adapted from [218]. 
Abbreviations: CSCs, cancer stem cells. 
 
5.1. Clonal Evolution Model 
 
The clonal evolution model assumes that during tumorigenesis and tumor 
evolution, cancer cells display different levels of genetic instability, harboring 
additional genetic aberrations. Such alterations lead to the development of a 
cancer cell population branched in different subpopulations, where each 
subpopulation acquires specific genetic aberrations. Thus, the most frequent clone 
in the tumor cell population is assessed by the tumor features and by the 
assemblage of selective pressures it is subjected to. Looking at the type and effect 
of each mutation that can occur along time, some of these mutations can confer a 
biological advantage for a certain cancer cell population leading consequently to 
clonal expansion [216, 218]. As denoted previously, clonal expansion may be also 
triggered by different epigenetic mechanisms that can increase the malignant 
potential of a given clone [219].  
 Clonal evolution model Cancer stem cell model 
Tumorigenic cells Any cell CSCs 
Tumor cells organization 
 
Stochastic Hierarchical 
Capacity of self-renewal 
with asymmetric divisions 
 
Not applicable 
CSCs have the ability to self-
renew indefinitely while 
terminally differentiated cells 
have a limited proliferative 
propensity 
 
Progression Driven by the fittest clone 
under an assemblage of 
selective pressures 
 
Driven by CSCs which 
correspond to a small 
subpopulation of the tumor 
bulk 
 
Source of heterogeneity Genetic and phenotypic 
heterogeneity 
Initially believed as largely 
phenotypic, although recent 
studies have demonstrated 
that CSCs may be genetically 
heterogeneous within a tumor 
Source of resistance to 
therapy 
Selection of resistant 
subclones containing specific 
genetic or epigenetic 
aberrations 
CSCs 
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As also depicted above, this model is mostly related with the effect of a 
certain mutation that can drive progression, like driver mutations, which can arise 
from passenger mutations, depending on the different selective pressures 
continuously existent in the tumor microenvironment [208, 209].    
The mutational rate during tumor progression can vary, increasing thus the 
heterogeneity within the tumor. As a consequence, tumors having a higher genetic 
complexity have a greater diversity of genetic aberrations that can be subjected to 
selective pressures. Thus, the chances of having a clone that can prevail under a 
new set of selective pressures are higher than in tumors where intra-tumor 
heterogeneity is lower [216]. 
 
5.2. Cancer Stem Cell Model 
According to the CSC model, heterogeneity may occur as a result of cancer 
being hierarchically organized with a particular subset of cancer cells called CSCs 
at the apex, having the ability of stemness [220, 221]. Such cells can theoretically 
explain certain phenomena of cancer such as resistance to chemo-radiation 
therapy, tumor relapse and metastasis [222]. Due to their different capabilities 
(self-renewal, multi-lineage differentiation through symmetric and asymmetric 
divisions), CSCs can be fundamentally important in predicting the biological 
aggressiveness of a cancer since it was believed that progenitor and differentiated 
cancer cells lose the stemness ability not being able to contribute to tumor 
aggressiveness [223]. The identification of the population able to form tumors in a 
relatively permissive environment is mostly based on cell-surface markers, 
obtained from the analysis of normal SCs in the tissue of origin. In breast cancer, 
as few as 100 CD44+/CD24-/low/Lineage- breast cancer cells were demonstrated to 
efficiently form tumors when injected into mice [224], whereas the efficiency of 
cells with other phenotypes was inexistent. Such demonstration has highlighted 
the tenets of the CSC model by the existence of stem-like cells. It was clear, 
however, that the CD44+/CD24-/low surface markers are enriched for tumorigenic 
cells in some, but not all breast cancers [226]. As a consequence, the concepts of 
the CSC hypothesis are being doubtful due to the recent demonstration of a 
dynamic equilibrium between differentiated cells and CSCs: as CSCs can 
differentiate into terminally differentiated cells, such terminally differentiate cells 
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have also the ability to de-differentiate into a CSC state [225]. Moreover, the 
overlap between some phenotypic characteristics of CSCs and the phenomenon 
of EMT has embraced a definition of the CSC phenotype as a dynamic cell state 
rather than a distinct cell type [226]. In addition, there is now direct evidence to 
demonstrate that at least in some types of cancer (that is, acute lymphoblastic 
leukemia) intra-tumor genetic heterogeneity is present not only in terminally 
differentiated cells, but also in the CSC population as defined by xenograft 
experiments [227].  
Nonetheless and at least for certain malignant diseases, the CSC model is 
undoubtedly proved to be responsible for tumor progression and aggressiveness. 
Considering also the evidence for clonal evolution in the pathogenesis of cancer, it 
appears inescapable that both models should be integrated in order to explain 
intra-tumor heterogeneity [228]. 
     
5.3. Co-existence of CSC and Clonal Evolution Models 
It is currently well known that most solid tumors show a wide genomic 
instability [229]. In fact, a large diversity of molecules responsible for the 
maintenance of the integrity of the genome is affected by genetic alterations which 
have become well-known drivers of oncogenesis [230]. For example, in a disease 
like chronic myeloid leukemia, already proved to be driven by SCs, clonal 
evolution can co-exist when imatinib is administered: the malignancy becomes 
tumor-resistant due to the emergence of clones carrying mutations in the target of 
imatinib [231]. Besides that, the progression of chronic myeloid leukemia into 
acute lymphoblastic leukemia blast crises is caused by the development of 
subclones that contain inactivating lesions in the cyclin-dependent kinase inhibitor 
2A (CDKN2A, also known as ARF) gene [232]. Such evidences suggest that both 
the CSC and the clonal evolution models can be seen as a major complex model 
rather than being mutually exclusive. Even with the notion that cancer cells may be 
genetically similar, they may occupy different positions in a differentiation 
hierarchy, reflecting thus the physiological hierarchy of the tissue of origin. Also, a 
single tumor may comprehend several CSC clones that are genetically different, 
but these cells can still have a common ancestor that sustained the first oncogenic 
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mutation. In this way, the assays and understandings recently brought into cancer 
research by the CSC field may be covered over the genetic data [228] (Figure 6).  
 However, and as we develop a more complete understanding of genetic 
heterogeneity within tumors, there may be some cancers in which genetic 
heterogeneity is the main driver of phenotypic and functional heterogeneity. As so, 
new models of cancer heterogeneity and plasticity may emerge that can be more 
important than the clonal evolution or the CSC model [233].    
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Theoretical synthesis of the clonal evolution and CSC concepts. Top to bottom: clonal 
evolution model. 1. A first oncogenic mutation (lightning arrow) occurs in a SC of a normal 
epithelium, leading to the formation of a genetically homogeneous benign lesion. 2. A second 
mutation occurs in one of the cells in the benign lesion leading to the growth of a malignant clone 
with invasive potential within the primary tumor. 3. A third mutation occurs in a cell within the 
malignant subclone resulting in the entry into the blood vessel for distant metastasis. 4. A final 
mutation give rise to a tumor completely taken over by cells that behave as CSCs. Left to right: at 
each stage of this clonal evolution process, tumors and subclones within tumors contain cells that 
behave as CSCs. Since the final hit (4) causes all cells to behave as CSCs, the CSC concept 
become meaningless at this stage. Adapted from [228]. 
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6. Cancer Stem Cells 
 
 
6.1. Origin of the CSCs 
Although the concept that cancer may arise from a small cell population 
with SC characteristics has been proposed since more than 150 years, new 
evidence have given an impetus to it through new advancements on SC research. 
At the present, the origin of CSCs can be explained by three major hypotheses 
including the (1) malignant transformation of normal SCs, (2) dedifferentiation of 
mature cancer cells through EMT and (3) induced pluripotent cancer cells. The 
first hypothesis lies on the belief that CSCs arise from somatic stem or progenitor 
cells with genetic or epigenetic alterations [234-236]. The long-lived nature of 
somatic SCs means that they are potential targets for the multiple accumulated 
mutations that lead to malignancy [51]. Although a SC origin for CSCs has to be 
determined empirically, a number of adult SCs have been shown to undergo 
spontaneous transformation in vitro to generate tumorigenic SCs [237-241]. 
Theoretical evidences that supports this assumption is the notion that only adult 
SCs with self-renewal and differentiation abilities could accumulate several 
mutations along an acceptable time to acquire a malignant potential, considering 
the low mutational rate in a normal somatic cell. Also, and due to the functional 
similarities between CSCs and SCs, it is suitable to consider SCs as the origin of 
CSCs [242]. However, the demonstration of the ability that a differentiated tumor 
cell obtains to self-renew through the EMT gave rise to a new assumption that 
CSCs can be enriched within an existing malignancy [243]. The suggested 
mesenchymal phenotype in normal BSCs and BCSCs and the reported gene 
expression characteristic of EMT led to this hypothesis, which was further 
corroborated in other cancer types with the co-expression reported of EMT and SC 
markers [243-245].  
The third theory of the origin of CSCs postulates that endogenous 
reprogramming or residues of the embryo are the source of CSCs. The recent 
improvements of induced pluripotent stem cells (iPSCs) artificially derived from an 
adult somatic cell have been used to explain the transformation of normal cells into 
tumor cells [246]. Nonetheless and has related above, induced pluripotency and 
oncogenic transformation can be seen as a connected process rather than being 
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models mutually exclusive. In fact, the specific tumor microenvironment existing in 
each cancer types also influence the behavior of several subsets of cancer cells 
that can act in different ways [247, 248]. 
 
6.2. CSC Niche 
With the discovery of CSCs, attentions naturally turned to the importance of 
the interactions of cells with their microenvironment [249]. The so called CSC 
niche comprehend different types of cells (niche cells, stromal cells, immune cells 
and vasculature) that surrounds the CSCs and also, secreted factors derived from 
these cells offering a “fertile territory” for CSCs to propagate [250]. Hence, for 
CSCs that exhibit stem cell-like features and have the capability to regenerate the 
bulk of tumor cells without losing their self-renewal propensity, the CSC niche act 
as a microenvironment regulatory system for these cells. [251]. Given the 
complexity of SCs, internal and external signals must exist in order to assure a 
correct balance between SCs and their progeny. While the internal signals 
(molecular pathways) are responsible for differentiation monitoring of SCs, 
external signals (cells from the microenvironment) must assure the correct 
anchorage of SCs to their niche and also to segregate factors responsible for 
quiescence and an undifferentiated state maintenance of SCs [252]. Considering 
that normal SC niches are also known to serve as CSC niches, the detachment of 
CSCs from their niche leads to their asymmetric or symmetric division (Figure 7). 
Numerous studies suggested that the CSC niche is essential for the production 
and development of CSCs [253-255], like their existence near the endothelial cells 
(supposed to stimulate stemness through certain factors like Notch), in gliomas 
[254, 255]. Likewise, activin and nodal secretory proteins were shown to be 
produced, apart from CSCs, by stellate cells, stimulating CSCs in a paracrine 
fashion [256]. Concretely, in breast cancer, mesenchymal cells were proved to 
support CSCs through a signaling loop modulated by Interleukin-6 (IL-6) and 
chemokine C-X-C motif ligand 7 (CXCL7) [257].  
Other important studies observed that CSCs respond to anti-tumor agents 
differently, both in vitro and in vivo, strengthening the role of CSC niches in 
response of CSCs to a given therapy [258]. In fact, the demonstration of the 
inability of less malignant tumors to form new tumors following implants into mice 
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supports the notion that tumor microenvironment can be determinant for the fate of 
certain tumor cells [259]. Considering that the major analysis studies of CSCs are 
dependent on CSC marker selection, the success rate of xenotransplantation 
assays may be compromised due to the loss of niche-derived factors upon the 
isolation of tumor cells for experimental designs [260]. In this way, it is plausible to 
assume that tumor microenvironment is crucial for the malignant progression of 
CSCs. It remains to be more fully elucidated what role stromal cells play in 
shaping this unique microenvironment, even if these cells were reported to 
regulate the invasive phenotype of BCSCs and to control tumor invasion. The 
mechanisms by which CSC regulation occurs have yet to be fully determined 
[242].  
 
 
 
 
 
 
 
 
Figure 7. CSCs have two abilities, self-renewal and differentiation potency. Thus, the detachment 
of CSCs from their niche leads to their asymmetric or symmetric division. Adapted from [261]. 
 
6.3. The Role of Quiescence in CSCs  
Stem cell quiescence is extremely important for cancer therapy since that 
quiescent CSCs are frequently resistant to both conventional chemotherapy and 
targeted therapies contributing for tumor relapse and discontinuation of treatment 
[262]. Sparse knowledge about quiescence mechanisms has however limited 
significant advances in targeting quiescent CSC populations that are specifically 
resistant to drugs. Nonetheless, recent discoveries suggest that the quiescent 
state is not just a passive state but, instead, actively regulated by several intrinsic 
mechanisms. Quiescent SCs are believed to be sensitive to environmental 
modifications responding through the re-entrance in the cell cycle for proliferation. 
In fact, it is proposed that CSCs may adopt the quiescent state to resist metabolic 
stress and to preserve their genomic integrity. Quiescent CSCs may be prompted 
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for activation by specific energetically favorable mechanisms that are compatible 
with the low metabolic state of quiescence [263]. Such modulation of these cells 
can consequently generate rapid and global responses needed for activation. This 
assumption is based through recent studies that have provided a better 
understanding of the regulatory mechanisms that control SC quiescence. A family 
of miRNAs was shown to have a preponderant role in regulating G0 to G1 
transition and cell cycle progression of SCs [264]. Related to breast cancer, 
different signaling pathways such as Hedgehog, Notch and Wnt have been 
implicated in multiple aspects of CSC quiescence [265-268]. 
High-throughput analyses of various SC subpopulations have recently 
provided valuable information on the molecular signatures of quiescent SCs in 
different tissue compartments. However, each pathway needs to be tested in 
studies of SC quiescence in vivo to determine the functional relevance. Such task 
is still extremely challenging due to the high levels of heterogeneity existing in 
cancer, especially in breast cancer, demanding thus more efforts in this field [269].  
 
6.4. CSCs and Intra-tumor Heterogeneity 
Intra-tumor heterogeneity denotes the coexistence of subpopulations of 
cancer cells that differ in their genetic, phenotypic or behavioral characteristics 
within a given primary tumor and between a given primary tumor and its 
metastasis. This diversity can be attributed to genetic and epigenetic factors and 
to non-hereditary mechanisms such as adaptive responses or fluctuation in 
signaling pathways [206, 270]. CSCs have different combinations of genetically 
derived cells with particular predispositions for growth, survival and dominance in 
the tumor micro-environment [270]. Looking at the CSC model, which postulates 
that disparities in the differentiation status between individual tumor cells lead to 
different functional properties within these cells, non-genetic factors may also 
contribute to tumor heterogeneity [242].    
 Different clinical outcomes are currently being explained by intra-tumoral 
phenotypic heterogeneity [257]. However, the frequency of CSCs in different types 
of cancers are also associated with aggressive forms of cancer, what in turn led to 
the assumption that CSCs are more prone to be resistant to treatment with a 
higher metastatic propensity than non-CSCs. In this way, it is plausible to assume 
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that subpopulations of cancer cells within a tumor may carry their own group of 
CSCs, but these cells and non-CSCs will share heritable genetic and epigenetic 
alterations. Inter-tumor heterogeneity of CSCs has also been identified due to the 
variations seen between features and prevalence of CSCs among different stages 
of cancer [271].    
 As referred above, the attempts to identify, isolate and characterize CSC 
populations are mostly dependent on cell-surface markers, obtained from the 
analysis of normal SCs in the tissue of origin [247]. Thus, a correct validation and 
selection of stem-cell marker is demanded in order to achieve solid and consistent 
results regarding this field. However, and due to the existence of a plethora of 
stem-cell markers for each type of cancer, different stem-like phenotypes were 
already been demonstrated to have different clinical outcomes for the same 
cancer. Specifically, in breast cancer, several proteins were reported to have stem 
properties that are currently being used to predict breast cancer aggressiveness 
and behavior [272].   
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7. Breast Cancer Stem Cells 
 
In the last two decades, breast cancer research has majorly focused in the 
identification, isolation and characterization of BCSCs. In order to do so, some 
genes having stem properties were studied and their corresponding proteins were 
subsequently validated as BCSC markers [224, 273]. As a consequence, a 
plethora of studies were published describing the impact of BCSCs identified by 
these established BCSC markers, like CD44, CD24 and ALDH1 as tumor initiating 
cells in breast cancer progression with high propensity to metastasize and to be 
resistant to therapeutic treatments [273-275]. With the increasing evidences for 
such ability, researchers attempted to demonstrate which genes or gene signaling 
pathways could potentially contributed for the tumorigenic potential of BCSCs. In 
fact, Notch, Wnt/β-catenin, or Hedgehog signaling pathways were shown to be 
deregulated in subpopulations of these cells [276, 277]. With the upcoming 
evidences regarding the effects of the stroma and the microenvironment in breast 
tumor progression, several genes were also reported to be associated with BCSCs 
[278]. The phenomenon of EMT and mesenchymal-epithelial transition (MET) in 
breast cancer cells during tumor progression was also an important discovery 
associated to BCSCs as an explanation for their ability to invade and to colonize 
other parts of the body, which has indeed questioned some of the tenets of the 
CSC model [225]. With all this knowledge, targeting BCSCs for breast cancer 
treatment was demanded and currently, some important inhibitors targeting 
subpopulations of BCSCs or gene signaling pathways that regulate these 
subpopulations are reported to be strongly effective [279, 280].  
One concern has however changed the definition of BCSCs: the breast 
cancer heterogeneity [218]. Due to the observations that not all BCSC markers 
were expressed in all breast cancer types, a research for different BCSC markers 
and different combinations of these markers that could be restricted to a specific 
breast cancer subtype or associated to aggressive forms of this disease has been 
ongoing [281, 282]. As a consequence, different BCSC phenotypes were 
described and characterized and in the future, other molecuels will be reported to 
have stem properties. Beyond the tenets of the CSC model, it is important to 
define which BCSC phenotypes have high tumorigenic potential and also high 
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ability to resist to therapeutic agents [283]. Moreover, it is also crucial to determine 
which oncogenes or tumor suppressor genes, other than those already described, 
are consistently mutated within these phenotypes and are able to drive 
tumorigenesis.  
In ductal breast cancers, a large study comprehending 12 different markers 
were immunohistochemically characterized showing that the prevalence of stem 
cell-like and more differentiated markers varies according to tumor subtype and 
histologic stage [284]. For that reason, a concise review is here presented 
regarding the implications of the most studied BCSC markers and BCSC 
phenotypes in breast cancer progression and treatment as well as the description 
of promising inhibitors able to target these cells. 
 
7.1. CD44+/CD24-/low Phenotype 
The combination of the BCSC markers CD44 and CD24 is by far the most 
extensively studied and undeniably the most contentious. The pioneering study by 
Al-Hajj et al showed that as few as 100 CD44+/CD24-/low Lineage- cells in patients 
with breast cancer could form tumors in mice, whereas tens of thousands of cells 
with alternative phenotypes failed to do so [224].  
Immunohistochemically, breast cancer tissues were investigated for the 
prevalence of CD44+CD24-/low tumor cells and their prognostic value. In a study 
including 136 patients with and without recurrences, the prevalence of 
CD44+/CD24-/low cells was ≤10% in 78% of cases and >10% in the other 22%. 
However, no significant correlation between the prevalence of this phenotype and 
tumor progression was noticed nor significant differences was seen between 
recurrence, DFS or OS [285]. In another study comprehending 95 patients with 
IDCs subjected to mastectomy, radiotherapy, chemotherapy, and axillary lymph 
node dissection, CD44+/CD24-/low cancer cells were shown to be abundant in the 
basal subgroups and absent in HER2-positive tumors [286]. This phenotype was 
also associated with BRCA1 mutational status which was correlated with basal-like 
tumor status and despite its association with increased poor prognostic features, it 
was not able to predict OS [287]. Regarding such important studies, the 
CD44+/CD24-/low phenotype has not a distinct prognostic value but is enriched in 
basal-like breast cancer subtype.  
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Gene expression profiling of CD44+/CD24-/low breast cancer cells revealed a 
gene signature of 186 genes associated with invasion and poor prognosis [288, 
289]. This signature was enriched in genes related to cell cycle, calcium-ion 
binding, chemotaxis, differentiation, protein transport, signal transduction and 
ubiquitination. Among these genes, this phenotype was observed to express high 
levels of IL-1 alpha, IL-6, IL-beta and urokinase plasminogen activator which 
predisposed to distant metastases (table 3). 
The enrichment of CD44+/CD24-/low cells demonstrated in primary breast 
tumors following radiation and chemotherapy has suggested an innate resistance 
to standard treatments [275]. The presence of ATP-binding cassette (ABC) 
transporters (which confers resistance to chemotherapeutic agents) highly 
expressed in a subpopulation of CSCs containing these markers has led to such 
assumption [290, 291]. In fact, the ability of these cells to reproduce, in an in vitro 
model following at least four generations of xenograft transplanted mice, has also 
suggested a significant role in tumor relapse and metastasis [292]. Potential 
mechanisms of chemotherapy and radiation resistance associated to this 
phenotype were shown to include the presence of lower concentration of reactive 
oxygen species, cell dormancy, efficient DNA repair mechanisms, overexpression 
of EMT markers, Wnt/β-catenin, Hedgehog and Notch signaling pathways and 
STAT1 and STAT3 signaling activation [276, 243, 293-298]. As a consequence, 
the CD44+/CD24-/low phenotype in breast cancer is currently being assessed as a 
therapeutic target.     
One of the most promising therapeutic agents belongs to the class of 
gamma-secretase inhibitors (MK0752) that was recently administered in patient-
derived tumor xenograft in combination with docetaxel. This inhibitor was reported 
to improve the docetaxel activity leading to a decrease of CD44+/CD24-/low tumor 
cells, to a reduced mammosphere forming activity and consequently, to the 
inhibition of tumor formation after serial transplantations. With these results, a 
phase I clinical trial in advanced breast cancers that did not respond to standard 
treatment was developed culminating in a decrease of CD44+/CD24-/low tumor cells 
and in the reduction of the tumor bulk [279]. This inhibitor is also being tested in 
combination with endocrine therapy (tamoxifen or letrazole in early stage breast 
cancer patients) and chemotherapy (docetaxel in locally advanced or metastatic 
breast cancer patients) [299]. 
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Other inhibitor from the same class such as PF-03084014 was also 
administered in a Phase I trial for the treatment of advanced breast cancers being 
able to reduce Notch activity and to considerably decrease tumor cell migration 
and mammosphere forming efficiency [299]. Its ability in decreasing self-renewal 
capability and expression levels of Notch target genes was also demonstrated in in 
vivo studies [300].     
Another promising compound for breast cancer treatment is metformin, a 
drug generally used for anti-diabetic therapy. Metformin have been shown to target 
preferentially CD44+/CD24-/low cell subpopulations in different molecular subtypes 
of breast cancer cell lines and to have a synergistic effect in eradicating CSCs 
upon its administration with doxorubicin [301, 302]. Indeed, this compound is 
believed to interfere directly with the tumorigenesis of CD44+/CD24-/low tumor cells 
and to prevent neoplastic mammary lesions [303]. Other promising compounds 
are being tested in order to target CD44+/CD24-/low tumor cells (table 3), although 
their potential still need to be proved [304-306].   
With all the experimental studies done regarding this phenotype it became 
clear that the CD44+/CD24-/low surface markers are enriched for tumorigenic cells 
in some, but not all breast cancers. Hence, the validity of the combination of these 
markers as a definition of BCSC has been called into question and additional 
markers have been reported like ALDH1 [307].   
 
7.2. ALDH1 
ALDH1 is broadly used as a functional marker in various types of cancer.  
Ginestier et al were the first to demonstrate the ALDH1 activity as a marker of 
stemness in normal and malignant breast cells. They were able to generate a 
stable tumor via orthotopic injection of 500 ALDH1-positive cells (evaluable by the 
ALDEFLUOR assay) into the mammary fat pads of Non-obese diabetic/severe 
combined immunodeficiency (NOD/SCID) mice. Such tumorigenic ability of 
ALDEFLUOR positive cells was also seen to be increased when shared with the 
CD44+/CD24-/low phenotype, since that only 20 of such cells were sufficient to 
generate tumors in animals [273]. Nonetheless, functional studies revealed that 
ALDH1+ cells were more prone to form colonies and tumors than CD44+/CD24-/low 
cells and also to be more chemoresistant [273, 308].     
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Several immunologic studies have attempted to assess ALDH1 as a 
prognostic marker in breast cancer. In the same study of Ginestier et al, a cohort 
comprehending 481 breast tumors from 2 independent breast tumors showed a 
prevalence of 30% for ALDH1 positivity and a correlation with high histologic 
grade, HER2 overexpression and absence of ER and PR expression [2]. ALDH1 
was also demonstrated to be an independent prognostic factor and the same was 
obtained in a group of 80 patients who received breast-conserving therapy. 
However, no association between ALDH1 tumor staining and micrometastatic 
disease was noticed [309]. In a larger cohort of more than 200 primary breast 
cancer patients, Morimoto et al reported a tendency for a worse prognosis with 
high ALDH1 expression [310]. Nonetheless and regarding the type of cells 
expressing ALDH1, a well-designed study from Resetkova and colleagues found 
that ALDH1 expression in the stromal compartment of 2 cohorts of triple-negative 
breast tumors had prognostic significance although being associated with good, 
rather than poor DFS [311].  
ALDH1 expression and clinical outcomes were also explored in 
inflammatory breast cancers (a particularly lethal form of breast cancer 
characterized by exaggerated lymphovascular invasion) revealing that ALDH1 
expression was a predictive factor for early metastasis and decreased survival 
[312]. Contrarily, in another study, no significant correlation between ALDH1 
expression and clinicopathological variables was obtained, despite a trend toward 
OS association [313].     
With all these contradictory results, the reliability of ALDH1 expression as a 
clinical predictor of response to treatment is doubtful enhancing thus the need for 
a standard protocol and evaluation process as well as the necessity to consider 
the differences between whole tissue staining vs tissue microarray staining [314]. 
Consistent findings between the reported studies are shown in table 3.    
Functional observations associated with ALDH1 are the increased levels of 
Notch and β-catenin which regulate the deacetylation of ALDH1 increasing its 
tumorigenicity in vivo and contributing to a poor clinical outcome. Increased 
expression of Hipoxia Inducible Factors 1 and 2α was also shown to be associated 
with ALDH1 activity which is believed to raise the metastatic propensity of 
ALDH1high cells [277, 315, 316]. Besides that, increased expression of HOXA1 and 
MUC4 were associated with high ALDH1 activity contributing also for tumor 
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relapse and metastasis. TGFβ2 signaling pathway activation was also shown to be 
involved in the pathological regulation of ALDH1 in breast cancer [317-319]. 
Using the ALDHhigh/CD44+/CD24-/low and ALDHhigh phenotypes, Charafe-
Jauffret et al and Croker et al provided the first direct experimental evidence 
implicating ALDHhigh cells in breast cancer metastases in vivo, respectively. Cells 
with a CSC phenotype characterized by ALDH activity were shown to have an 
improved ability for metastatic behavior in vitro (adhesion, colony formation, 
migration, and invasion) and/or metastases in vivo, supporting the hypothesis that 
CSCs might act as metastasis-initiating cells [283, 317, 320-322].  
ALDH1 is also involved in metabolizing chemotherapeutic drugs so its 
inhibition was believed to contribute for the reduction or elimination of BCSCs. 
Indeed, significant resistance to sequential paclitaxel- and epirubicin-based 
chemotherapy was found in tumor cells expressing ALDH1 [304]. The inhibition of 
ALDH1 activity was also demonstrated to reduce stem-like properties and 
resistance to drugs and radiotherapy. As a consequence, these findings have 
emphasized the need to target ALDH1+ tumor cells in breast cancer treatment 
[322].   
Even though the sparse existence of studies evaluating the impact of 
pharmacological or immune targeting of ALDH on metastases in vivo, most of 
them showed a decrease of the metastatic burden. In this way, rationalized small 
molecule discovery has been proposed as a viable methodology in order to 
overcome these difficulties and such improvement led to the current development 
and generation of isoform-specific ALDH inhibitors (table 2). Salinomycin (an 
inhibitor of Wnt pathway) is currently the most promising chemotherapeutic drug 
demonstrated to inhibit the distinctive phenotypic properties of CSCs rather than 
by inducing apoptosis of these cells [280]. These findings underline the potential 
therapeutic value of targeting these properties to reduce the likelihood of tumor 
recurrence following chemotherapy.  
Despite the enrichment of CSCs in ALDH1+ populations reported in several 
tissues, enzymatic activity measured by ALDEFLUOR alone is much more 
transient than the expression of traditional surface markers. The usefulness of 
ALDH1 activity as a sole CSC marker may than be limited but can be increased if 
staining cells simultaneously for ALDH1 activity and for more stable markers like 
CD44 or CD133 [323].  
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7.3. CD44+/ALDH1+/high Phenotype 
The importance of ALDH1 activity in breast cancer has been explored alone 
or in combination with the CD44+/CD24-/low phenotype. However, analysis of tumor 
samples revealed that only 1% of the ALDH-positive cell population also had the 
CD44+/CD24-/low/Lin- phenotype reported for BCSCs [273]. In fact, an increase in 
the population of ALDH1+ cells but not CD44+/CD24-/low cells has been observed in 
breast cancer tumor biopsies after neoadjuvant treatment [223]. Considering the 
limited usefulness of ALDH1 activity as a sole BCSC marker, other combinations 
have been studied like the CD44+/ALDH1+/high phenotype. This phenotype was 
recently demonstrated to have high tumorigenic ability in breast cancer cell lines 
and also high metastatic propensity, being resistant to standard cancer therapies 
[322].  
An interesting in situ method to define CSCs in FFPE breast cancer tissues 
through a quantitative immunofluorescence method was designed by Neumeister 
and colleagues in order to measure the co-expression of CD44, ALDH1 and 
cytokeratin. Using a retrospective collection of 321 node-negative and 318 node-
positive patients, localization of CD44+/ALDH1+ cells was shown within the 
epithelial (cytokeratin) compartment of breast tumor tissue. Even if this co-
expression was seen in variable sized clusters and only in 6% of cases, such 
combination showed significantly worse outcome, being able to identify high risk 
patients in breast cancer [281]. Our research group has also studied the co-
expression of CD44 and ALDH1, and remarkably, such combined expression was 
seen to be higher in DCIS lesions when compared with IDCs of the breast, 
enhancing the tumorigenic potential of these putative BCSCs [324]. More 
interestingly, we also demonstrated, in a cohort comprehending 250 patients 
having different benign and malignant breast lesions, that the CD44+/ALDH1+ 
phenotype was significantly increased in high-grade DCIS when compared with 
IDCs. Moreover, this phenotype was found to be predominantly in a quiescent 
state (negativity for Ki-67 proliferation marker) rising some questions about the 
real role of dormancy in BCSCs [325]. 
A gene expression analysis study revealed an increased expression of 
Notch and Wnt/β-catenin signaling pathways in CD44+/ALDH1+ breast cancer cells 
isolated from an IBC cell line [326]. However, and concerning this phenotype, 
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further genetic and even epigenetic analysis are demanded to better understand 
its behavior in breast cancer progression. Like CD44+/CD24-/low and/or ALDH1+ 
tumor cells, it would be also interesting to depict the mechanisms that drive the 
progression of CD44+/ALDH1+ tumor cells. 
Indeed, Croker et al have directly inhibited ALDH activity with the specific 
ALDH inhibitor diethylaminobenzaldehyde (DEAB) and indirectly through all-trans 
retinoic acid (ATRA). They isolated ALDHhigh/CD44+ and ALDHlow/CD44- 
populations and demonstrated that ALDHhigh/CD44+ human breast cancer cells 
were resistant to certain chemotherapy drugs [322]. For that, they subjected both 
populations to treatment with doxorubicin, paclitaxel or radiation in the presence or 
absence of DEAB or ATRA and concluded that the reduction in cell viability was 
significantly greater in the ALDHhigh/CD44+ population. Furthermore and in contrast 
to ALDHlow/CD44- cells, ALDHhigh/CD44+ cells showed increased basal activity in a 
series of DNA response proteins including p-glycoprotein, glutathione-S-
transferase pi and/or CHK1 checkpoitn homolog 1 (table 3). 
Although such results enhance the need of targeting CD44+/ALDH1+ tumor 
cells in breast cancer, no other agents or drugs have been developed to directly 
target this phenotype. Only inhibitors that target CD44+/CD24-/low tumor cells or 
ALDH1+ tumor cells were shown to be promising. Despite the current 
improvements regarding the adverse effects of ALDH1 and CD44 for breast 
cancer treatment, additional studies in order to infer about the tumorigenic and 
metastatic ability of CD44+/ALDH1+/high tumor cells combined with their quiescence 
status still have to be depicted. Moreover, the development of additional promising 
inhibitors to target this phenotype is also demanded. 
 
7.4. Prominin-1 (CD133)  
 CD133 has been recently included in CSC research. It is also named 
Prominin-1 for its prominent location on the protrusion of cell membranes being 
the first identified gene in a class of novel pentaspan transmembrane 
glycoproteins. Although it was initially considered to be a marker of hematopoietic 
SCs, CD133 mRNA transcript is also found in normal non-lymphoid hematopoietic 
tissue [327] and has been shown to play a role in SC migration and asymmetric 
division [328]. CD133 was reported to be overexpressed in several solid tumors, 
Chapter 1. General Introduction 
 
49 
 
[329, 330] including colon cancer and glioblastoma [331, 332]. In IBCs, CD133 
expression was demonstrated by Liu et al [333] where they assumed that its 
expression could be of help in a more accurately prediction of breast cancer 
aggressiveness and determination of the most suitable treatment. Actually, in 
BRCA1-associated breast cancer cell lines, CD133+ sorted cells were shown to 
contain CSC properties including a greater colony-forming efficiency, higher 
proliferative output and greater capability to form tumors in NOD/SCID mice [334]. 
Moreover, CD133 was also proved to be suitable in the identification of CSCs in 
triple-negative breast cancers through several in vitro  [335, 336] and in vivo 
studies [337]. In addition, the recent use of CD133 to detect circulating tumor cells 
in triple-negative breast cancer patients [338, 339] has increased the attention of 
this marker, emphasizing its role in the determination of the prognostic and 
predictive value in this breast cancer subtype. Expression of CD133 was also 
recently reported in 22 out of 25 cases of inflammatory breast cancer [282]. Taken 
together, these interesting results increase the need of more advanced research to 
understand the role of CD133 in BCSCs.   
Expression of SC associated genes, such as Notch1, ALDH1, Fgfr1 and 
Sox1, was shown to be increased not only in CD44+/CD24-/low but also in CD133+ 
breast cancer cells [334]. Xenograft-initiating breast cancer cells enriched in 
CD44+/CD49fhigh/CD133/2high cells were also shown to have elevated levels of 
Nanog, Sox2, and/or Bmi-1 [340]. Further extensive CD133 profiling in breast 
cancer have hence to be performed to define CD133+ breast cancer cells as tumor 
initiating cells in breast cancer tumors.  
Due to the increasing importance of CD133 expression in breast cancer 
progression, attempts have been made to correlate its expression with tumor 
relapse and resistance to chemotherapeutic agents. In fact, CD133 expression 
was reported to be correlated with tumor recurrence in breast cancer patients 
[341]. In drug-sensitive MCF-7 cells, only a small fraction of cells was found to be 
CD133+ [342]. In an interesting study, polymeric nanoparticles loaded with 
paclitaxel and surface functionalized with anti-CD133 antibody demonstrated 
efficient elimination of tumor initiating cells in vitro and significant inhibition of 
tumor-regrowth in vivo [343]. With such results, CD133 is regarded as a potential 
target for anticancer therapeutics, being possible to reduce tumor recurrence in 
breast cancer through the elimination of CD133+ cells. Thus, additional studies 
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investigating specific drugs that could efficiently target this protein are required in 
order to be applied in the clinic.  
 
7.5. Integrins 
The use of the integrins CD29 (β1) and CD49f (α6) in combination with 
CD24 was recently demonstrated to be able to identify mouse mammary SCs 
[344, 345]. Since that all previously described SC  markers were shown not only to 
identify normal mammary SCs but also to isolate mammary CSCs, Vassilopolus et 
al used CD24/CD29 and CD24/CD49f to successfully identify a subpopulation of 
mammary tumor cells [346]. Such demonstration highlighted hence the importance 
of CD29 and CD49f in BCSCs. CD49f heterodimerizes with either the CD29 or 
CD104 (β4 integrin) subunits to generate the CD49fCD29 and CD49fCD104 
integrins, which function primarily as laminin receptors [347]. Besides that, CD49f 
cooperates with receptor tyrosine kinases to communicate, bidirectionally, 
between the cell and the ECM. Interestingly, however, the CD104 subunit appears 
to be expressed at very low levels, if at all, in CSCs when compared to non-CSCs 
indicating that CD49fCD29 is the dominant integrin expressed by CSCs [348, 349].  
In mice, CD29 represents the predominant expressed integrin in mammary 
epithelial cells and is aberrantly expressed in human breast carcinomas 
contributing to diverse malignant phenotypes, including EMT, metastases and 
angiogenesis [349-352]. Moreover, in patients with IBCs, high CD29 expression 
was found to be associated with significantly shorter OS and DFS [353, 354]. In 
human breast cancers, CD49f integrin is overexpressed and was shown to be an 
independent prognostic factor [355]. CD49f+ cancer cells were also associated 
with a higher probability of distant metastasis after initial surgery and poor clinical 
outcomes with respect to both DFS and OS [356]. Additionally, normal human SCs 
and myoepithelial progenitor cells characterized by CD49high/EpCAM- cells were 
shown to express vimentin, a common EMT marker suggesting that some cells 
may be undergoing EMT [357]. Interestingly, an aberrant luminal progenitor cell 
population (EpCAM+/CD49f+) was also proposed to be the cell origin of BRCA1 
associated basal breast cancers [358]. 
Functional analysis revealed that while knockdown of CD29 or CD49f alone 
slightly decreased cell migration ability, knockdown of both genes caused a 
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profound effect to block their migration, suggesting an overlapping, yet critical 
function of both genes in the migration of BCSCs [346]. Such interesting finding 
supports the notion that both integrins can pair with each other in order to form 
heterodimers for ECM components such as fibronectin and laminin [347]. 
Consistent with the assumption that a malignant social network mediates cell–cell 
adhesion and communication between CSCs and their microenvironment [359], 
both integrins may be implicated in mediating such network. Specifically, 
CD29/CD49f integrins may mediate CSCs–stroma interaction, relaying ECM 
signaling to cellular machinery leading to the increased activity of CSCs in terms of 
viability, differentiation and metastasis [346].  
Although the CD29/CD49f integrins have been implicated in the function of 
breast and other CSCs [348, 349, 360], much needs to be learned about the 
contribution of these integrins to the genesis of BCSCs. It has been shown that 
either CD49f or CD29 contributes to therapy resistance, tumor relapse and 
metastases in breast cancer. As a consequence, the development of inhibitors that 
could potentially target these two integrins in breast cancer is required (table 3). 
Currently, interesting studies have been published with promising results in 
targeting these integrins like the use of short hairpin RNAs or micro-RNAs [361]. 
Targeting gene signaling pathways associated to these integrins or even specific 
kinases like FER (feline sarcoma-related) kinase that controls migration and 
metastasis of IBC cell lines by regulating CD49f- and CD29-integrin-dependent 
adhesion is also an interesting approach [362].   
 
7.6. BCSCs and Next-Generation Sequencing 
The continuous improvements of NGS technologies currently allow the 
analysis of hundreds of genes in just one population of cells, or even in one single 
cell [204, 363]. Such application opened a new window in the genomic field where 
a mutational, time-based lineage tree can now be delineated for a specific subtype 
of cancer considered to be highly aggressive. In this way and with NGS, it is 
possible to determine other genes from those already associated to be oncogenic, 
or, more importantly, to assess which mutated genes can be responsible to drive 
tumorigenesis considering the high levels of heterogeneity in cancers, especially in 
breast cancer [364]. In fact, NGS has recently been used for the analysis of the 
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molecular features of early stage breast cancer, leading to a genomic portrait of 
this disease. Within such portrait, TP53 and PIK3CA mutations were the most 
frequent genomic alterations found in all breast cancer subtypes. Clinical 
relevance of PTEN mutations and deletions as well as AKT1, BRCA1 or BRCA2 
mutations was also highlighted [211]. 
With this in mind and related to BCSCs, such technology would allow the 
definition of a mutational repertoire of each subpopulation of BCSCs here 
presented. Even using a small cohort, our research group was able to detect, 
through NGS, somatic mutations in CD44+/CD24-/low/Ck+/CD45- breast cells 
isolated from non-malignant and malignant breast lesions. Mutations affecting the 
TP53, NOTCH1, HRAS, AKT1, PTEN, CSF1R and RET genes were detected in 
the malignant lesions suggesting a heterogeneous molecular profile of these 
BCSCs [365]. Thus, a practical example would be the application of NGS in 
isolated BCSCs (defined by different combinations of BCSC markers) from primary 
tumors and their corresponding metastases in order to determine which gene is 
more frequently mutated (hotspot mutations) in each subpopulation of BCSCs. 
Such approach would be of great importance for the development of additional 
therapeutic drugs that could be promising for the most known BCSC markers 
(CD44, CD24 and ALDH1), but also for the discovery of new targets directly 
associated with other BCSC markers like CD133 or integrins.  
In the future, this growing technology will definitely revolutionize the CSC 
research with the upcoming of new gene signaling pathways directly involved in 
the progression of tumor initiating cells already proved to have stem properties, 
particularly in breast cancer [290].    
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Table 3. Characteristics of the different assessed BCSC phenotypes and BCSC markers. 
BCSC phenotypes/ 
BCSC Markers 
 
Tumorigenic potential 
 
Clinicopathological 
features 
 
Functional/mechanistic observations  
 
Clinical observations 
 
Inhibitors 
 
CD44
+
/CD24
-/low
 
 
Able to drive tumor 
formation when 
inoculated into 
NOD/SCID mice [224] 
 
Enriched in basal-like and 
claudin-low breast cancer 
subtypes [286] 
Associated with BRCA1 
mutational status [287] 
Poor prognosis [285] 
 
Increased levels of IL-1α, IL-.6, IL-β and uPA 
[288, 289]  
Increased expression of TWIST and SNAIL1 
[243, 293] 
Increased levels of Wnt/β-catenin, Hedgehog 
and Notch signaling pathways [294, 299] 
Low levels of ROS [276] 
Cell dormancy and efficient DNA repair 
mechanisms [296] 
Increased levels of ABC transporters, STAT1 
and STAT3 [291, 297, 298] 
 
Tumor recurrence [293] 
Resistance to radiation 
and standard treatments 
[275] 
High metastatic propensity 
[292]  
 
Short hairpin RNAs [366] 
Gamma-secretase inhibitors 
[279, 299, 300] 
Metformin.[301, 302] 
ATRA or vorinostat [367] 
Niclosamide [304] 
Disulfiram/copper [305] 
Cyclophosphamide [306] 
 
ALDH1 
 
Able to generate a 
stable tumor via 
orthotopic injection of 
ALDH1
+
 cells into 
NOD/SCID mice [273] 
 
Associated with poorer 
clinical outcomes including 
ER negativity, basal subtype 
and HER2-amplification 
[273, 310]  
 
Increased expression of Ki-67 and EZH2 [310, 
368] 
Increased expression of HIF-1/2α [315] 
Increased expression of HOXA1 and MUC4 
[317] 
Increased levels of TGFβ2, Notch and Wnt/β-
catenin signaling pathways [316, 319, 369] 
 
Tumor recurrence [284] 
Enhanced capacity for 
metastatic behavior [284, 
320] 
Resistance to sequential 
paclitaxel-and epirubicin-
based chemotherapy [304] 
 
DEAB [322] 
ATRA [322] 
Salinomycin [280] 
Disulfiram/copper [370] 
 
 
CD44
+
/ALDH1
+/high
 
 
Able to drive tumor 
formation when 
inoculated into 
NOD/SCID mice [283] 
 
Able to identify high risk 
patients in breast cancer 
[281] 
Enriched in high-grade DCIS 
[325] 
 
Increased levels of Notch and Wnt/β-catenin 
signaling pathways [326] 
High levels of p-glycoprotein, GSTpi, and/or 
CHK1 [322]  
Cell dormancy [325] 
 
Predicts distant 
metastases and OS [325] 
High metastatic propensity 
[322] 
Resistant to standard 
cancer therapies [322] 
 
DEAB [322] 
ATRA [322] 
 
CD133 
 
Ability to form tumors in 
NOD/SCID mice from 
BRCA1-associated 
breast cancer cell lines 
[334]   
 
Enriched in IBCs and 
particularly in TNBCs [335-
337] 
CTCs detection in triple-
negative breast cancer 
patients [338, 339] 
 
Increased expression of Notch1, ALDH1, Fgfr1 
and Sox1 [334] 
High levels of Nanog, Sox2, and/or Bmi-1 in 
CD44
+
/CD49f
high
/CD133/2
high 
breast cancer 
cells [340] 
 
Tumor recurrence [341] 
Resistant to standard 
cancer therapies [342] 
 
Paclitaxel and surface anti-
CD133 antibody [343] 
 
CD29/CD49f 
 
Enrichment of CD29 and 
CD49 in combination 
with CD24 for cancer-
initiating cells in primary 
breast tumors [346]  
 
CD29 associated with 
shorter OS and DFS [353, 
354] 
CD49f associated with poor 
clinical outcomes and 
regarded as a prognostic 
factor [355, 356] 
Increased expression of EMT markers [82, 
357] 
EpCAM
+
/CD49f
+
 breast cancer cells proposed 
to be the cell origin of BRCA1 associated 
basal breast cancers  [358] 
 
Tumor relapse [372, 373] 
High metastatic propensity 
[359] 
Resistance to therapy 
[374, 375] 
 
Combination of miR-9-3p 
with AZD6244 for CD29 
[360] 
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Breast cancer continues to be one of the major causes of female morbidity 
and mortality worldwide. Despite the main diagnostic and therapeutic innovations, 
the effect on mortality has been modest. Over the last decade, the notion that 
tumors are maintained by their own SCs, the so-called CSCs, has created great 
excitement in the research community. With the growing idea that these self-
renewing tumorigenic cells are mainly responsible for resistance to chemo-
radiation therapy and cancer relapses, several studies were done to identify 
putative CSCs in several solid cancers, like in breast cancer. 
However, and due to the high levels of heterogeneity associated with this 
disease, several BCSC markers have been identified and characterized, with 
some being associated to aggressive forms of breast cancer. Nonetheless, and 
among all BCSC markers identified until now, it is important to define which BCSC 
phenotypes have high tumorigenic potential and ability to resist to therapeutic 
agents. 
With this in mind, the general aim of this doctoral thesis was to characterize 
different BCSC populations in different stages of breast cancer progression. Thus, 
and using breast reduction specimens as well as non-malignant and malignant 
tissues, the following studies were performed in order to assess specific 
objectives: 
 
I. To compare two of the most reliable BCSCs markers, ALDH1 
and CD44 and to correlate their expression within different 
breast lesions. 
We aimed to explore a possible association between a high 
expression of SC markers and a specific type of lesion during breast 
cancer progression. Thus, ALDH1 and CD44 expression was 
immunohistochemically evaluated in non-malignant, DCIS and IDCs 
sample cores. 
 
II. To characterize the CD44+/ALDH1+/Ki-67- phenotype in non-
malignant and malignant breast lesions. 
A higher combined expression of CD44 and ALDH1 in DCIS was 
observed when compared with IDCs in objective I. In this way, we 
combined these BCSC markers with Ki-67 to evaluate quiescence in 
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order to identify, evaluate its distribution and estimate the mean 
percentages of CD44+/ALDH1+/Ki-67- cells in a series of normal, 
non-malignant and malignant breast tissues. Clinical relevance of 
this phenotype was inferred by associations with markers of breast 
cancer behavior, progression and survival. 
 
III. To characterize CD44+/CD24-/Ck+/CD45- breast cells through 
flow cytometry and massive parallel sequencing. 
Considering the well-defined CD44+/CD24-/low phenotype in breast 
cancer and the current improvements done in NGS technologies, we 
aimed to characterize, through flow cytometry, CD44+/CD24-
/Ck+/CD45- cells in frozen biopsy samples harboring different breast 
lesions. More importantly, we also aimed to determine which somatic 
mutations were associated to this phenotype isolated from frozen 
mastectomy samples, using the Ion Torrent Ampliseq Cancer 
Hotspot panel v2. 
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Summary  
 
Breast cancer epithelial cells with the CD44+/CD24-/low phenotype have been 
shown to possess tumor-initiating cells and epithelial-mesenchymal transition 
(EMT) capacity. Considering such important features, massive parallel sequencing 
can be an interesting approach to deepen the molecular characterization of these 
cells. We characterized CD44+/CD24-/Cytokeratin(Ck)+/CD45- breast cells through 
flow cytometry in 43 biopsy and 6 mastectomy samples harboring different breast 
lesions. The Ion Torrent Ampliseq Cancer Hotspot panel v2 (CHPv2) was used for 
the identification of somatic mutations in the DNA extracted from isolated 
CD44+/CD24-/Ck+/CD45- cells. E-Cadherin and vimentin immunohistochemistry 
was performed in the correspondent formalin-fixed, paraffin-embedded (FFPE) 
blocks. The percentage of CD44+/CD24-/Ck+/CD45- cells increased significantly 
from non-malignant to malignant lesions and was negatively correlated with tumor 
size. A significant association with estrogen receptor (ER) positivity, human 
epidermal growth factor type 2 (HER2) negativity and vimentin positivity was 
observed. The non-malignant lesion harbored only a single-nucleotide 
polymorphism (SNP). Mutations in the tumor suppressor p53 (TP53), NOTCH 
homolog 1 (NOTCH1), Phosphatase and tensin homolog (PTEN) and v-akt murine 
thymoma viral oncogene homolog 1 (AKT1) genes were found in isolated 
CD44+/CD24-/Ck+/CD45- cells from ductal carcinomas in situ (DCIS). Additional 
mutations in the colony-stimulating factor 1 receptor (CSF1R), ret proto-oncogene 
(RET) and TP53 genes were also identified in invasive ductal carcinomas (IDCs). 
The use of massive parallel sequencing technology for this type of application 
revealed to be extremely effective even when using small amounts of DNA 
extracted from a low number of cells. Additional studies are now required using 
larger cohorts to design an appropriate mutational profile for this phenotype.   
 
Introduction 
Although several studies have tried to identify breast cancer stem cells 
(BCSC) through cell surface marker profiles, agreement on their phenotypic 
characterization is still lacking. With the current demonstrations of several putative 
BCSC markers [1,2], it became unfeasible to obtain a universal combination of 
markers that could specifically identify BCSCs in all breast cancers. Breast cancer 
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heterogeneity as reflected by numerous histological subtypes, with variable clinical 
presentations and different molecular signatures also contributes to major 
drawbacks [3]. 
Indeed, intra-tumor heterogeneity leads to a single tumor to contain, at any 
given time, tumor cell populations displaying different molecular profiles and 
biological properties [4]. As a consequence, different BCSC phenotypes were 
described, with some being associated with aggressive forms of breast cancer [5, 
6]. Although the validation of the CSC model remains an ongoing task, it is 
important to define which BCSC phenotypes have high tumorigenic potential and 
ability to resist to therapeutic agents [7].  
We have previously demonstrated that the co-expression of the BCSC 
markers CD44 and ALDH1 in DCIS could be determinant for disease progression 
[8]. Nonetheless, the combination of the BCSC markers CD44 and CD24 
continues to be the most extensively studied. The pioneering study by Al-Hajj et al 
showed that as few as 100 CD44+/CD24-/low lineage- breast cancer cells from 
patients with breast cancer could form tumors in mice, whereas tens of thousands 
of cells with alternative phenotypes failed to do so [9]. Immunohistochemically, 
several studies have identified the CD44+/CD24-/low phenotype as being associated 
with poor prognostic features [1, 10].   
Gene expression profiling of CD44+/CD24-/low breast cancer cells revealed a 
gene signature of 186 genes associated with invasion and poor prognosis [11]. 
This signature was enriched in genes related to cell cycle, calcium-ion binding, 
chemotaxis, differentiation, protein transport, signal transduction and protein 
ubiquitination.   
The increment of CD44+/CD24-/low cells demonstrated in primary breast 
tumors following radiation and chemotherapy has suggested an innate resistance 
to standard treatments [14]. Potential mechanisms of chemotherapy and radiation 
resistance associated with this phenotype were shown to include the presence of 
lower concentration of reactive oxygen species, cell dormancy, efficient DNA 
repair mechanisms, overexpression of EMT markers, Wnt/β-catenin, Hedgehog 
and Notch signaling pathways and STAT1 and STAT3 signaling activation [12-18].  
The continuous improvements of Next-Generation Sequencing (NGS) 
technologies allow the analysis of hundreds of genes in just one population of 
cells, or even in one single cell [19, 20]. With NGS, it is possible to determine 
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which genes associated somatic mutations can be responsible to drive 
tumorigenesis, while considering the high levels of heterogeneity in cancers, 
especially in breast cancer [21]. Currently, standardized NGS kits are available 
and multiple studies have shown that these kits provide reliable sequencing results 
in routine cancer diagnostics, like the CHPv2 [22, 23]. Such assay includes 50 
genes known to be involved in the pathogenesis of many human cancers. 
In this study we aimed to identify CD44+/CD24-/Ck+/CD45- cells and 
determine their mean percentages in a cohort of frozen breast specimens 
consisting of non-malignant and malignant lesions and to correlate their frequency 
with clinicopathological markers of breast cancer progression. Moreover and 
through the CHPv2, we aimed to determine which mutated genes were associated 
with this phenotype.  
 
Materials and Methods 
 
Patient samples 
Biopsy and mastectomy samples from 49 patients were obtained from the 
Radiology, Surgery and Pathology Departments of Santo António Hospital (Porto 
Hospital Centre, Porto, Portugal) between 2013 and 2015 and the correspondent 
FFPE blocks of each patient were retrieved from the archives of the same 
Pathology Department. This study was approved by the local Ethics Committee 
and all patients gave the informed consent to participate. The fragments taken at 
the time of surgery were routinely processed by freezing in optimum cutting 
temperature (OCT) media. H&E-stained sections for each sample were 
microscopically analyzed by one experienced pathologist (CL). From this analysis 
and regarding the biopsy samples, 20 were considered to have benign breast 
lesions, including adenosis, fibroadenomas and ductal hyperplasias, 2 contained 
high-grade DCIS lesions and 21 harbored IDC lesions. Regarding the 6 
mastectomy samples that were also used for molecular analysis, one contained a 
fibroadenoma, 3 harbored DCIS lesions (one pure DCIS, and two DCIS within 
IDC) and 2 were confirmed to have IDC lesions (one triple-negative tumor and one 
luminal tumor). None of these patients had a family history of breast cancer. 
Pathology reports of each patient were retrieved to (1) confirm the existence of 
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each lesion diagnosed in each sample, (2) to confirm the absence of malignancy 
in samples that contained only benign lesions and (3) to confirm the presence or 
absence of invasion in the observed DCIS samples. Moreover, the following 
histopathologic variables for the malignant cases were available in the interim 
records: Elston-Ellis histologic grade, tumor size, lymph-node status, local 
recurrences, distant metastasis, ER, PR and HER2 status and Ki-67 proliferation 
index. The definition of hormone receptor status was assessed by 
immunohistochemistry, as routinely done in the Pathology Service. HER2 
ambiguous results were confirmed by Fluorescence in situ Hybridization. Low and 
high Ki-67 expression was defined according to the cut-off of ≤14% and >14%, 
respectively [24].   
 
Flow cytometry and cell sorting 
Frozen breast samples were thawed on ice and fat tissue was removed as 
far as possible. The remaining tissue was crudely minced with scalpels and 
disaggregated with 1 ml of Phosphate-buffered saline solution (PBS, pH 7.4) with 
0.2% of Bovine serum albumin (BSA) and 0.1% of sodium azide (PBS-0.2%BSA-
0.1%Azide). Cell suspensions were transferred to 5 ml, 75 x 12 mm, 
polypropylene tubes, centrifuged for 5 minutes at 400 x g and once again washed 
with PBS-0.2%BSA-0.1%Azide. The remaining pellets were suspended in the 
same buffer, and cells were counted. Cell fixation and permeabilization was made 
using the Fix & Perm® reagent kit (Invitrogen Corporation, Camarillo, CA) 
according to the manufacturer’s instructions. Briefly, 1 x 106 cells were incubated 
for 15 minutes at room temperature in the dark, in the presence of saturating 
amounts of mouse anti-human monoclonal antibodies (mAb) specific for CD44 
(clone G44-26, BD Biosciences, Franklin Lakes, NJ, USA), CD24 (clone ML5, BD 
Biosciences, Franklin Lakes, NJ, USA), and CD45 (clone 2D1, BD Biosciences, 
California, USA), conjugated with allophycocyanin (APC), phycoerythrin (PE) and 
Peridinin chlorophyll (PerCP), respectively. Fluorescence-minus-one (FMO) 
controls lacking either the anti-CD44-APC or anti-CD24-PE antibodies were used 
to distinguish positive and negative cell populations. After staining, all samples 
were washed twice with PBS-0.2%BSA-0.1%Azide, centrifuged (5 minutes, 400 x 
g), and incubated with 100 µl of Fix & Perm® reagent A (fixative medium) for 15 
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minutes at room temperature. After another two washes in the same conditions, 
the remaining pellets were incubated for 15 minutes at room temperature in the 
dark with 100 µl of Fix & Perm® reagent B (permeabilization medium), in the 
presence of saturating amounts of  mouse anti-human cytokeratin mAb (clone 
J1B3, Beckman Coulter, Marseille, France) conjugated with fluorescein 
isothiocyanate (FITC). An appropriate IgG1-FITC isotype control was run in 
parallel (clone 679.1Mc7, Beckman Coulter, Marseille, France). The labeled cells 
were washed twice in the same conditions, and suspended in 0.5 ml of PBS 
before analysis. All measurements were performed on a BD FACSCantoTM II Flow 
Cytometer. For each sample run, a minimum of 10 000 events were recorded. 
Flow cytometric data was analyzed using FlowJo X 10.0.7r2 (TreeStar, Ashland, 
OR, USA). Briefly, cells were gated on a forward scatter (FSC) versus side scatter 
(SSC) dot plot to exclude dead cells and debris. After exclusion of doublets, 
epithelial mammary cells were identified and hematopoietic cells were eliminated 
from the analysis by gating cells on cytokeratin-FITC versus CD45-PercP dot plots 
(Fig. 1). The percentages of CD44+/CD24-/Ck+/CD45- breast cells and the median 
fluorescence intensities of CD44, CD24 and Ck expression were retrieved for 
statistical analysis.  
For sorting and considering the purpose of this study, CD44+/CD24-/Ck+/CD45- 
breast cells from six mastectomy samples were purified. Cell sorting was 
performed on a BD Biosciences FACSAria operating at Pressure of 70 psi using a 
70 μm nozzle, using the gating strategy described above. Considering the low 
numbers of CD44+/CD24-/Ck+/CD45- breast cells sorted, cell purity was checked in 
cell populations defined as non-BCSCs (not CD44+/CD24-/Ck+/CD45- breast cells). 
A purity of more than 95% was obtained. Cell populations of interest were sorted 
into individual Eppendorf tubes and collected for DNA extraction (Table 5). 
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Fig. 1. Gating strategy for the identification of CD44
+
/CD24
-
/Ck
+
/CD45
-
 breast cells: (A), all cells 
were gated on a forward scatter (FSC) versus side scatter (SSC) dot plot to exclude dead cells and 
debris (B), epithelial mammary cells were identified and hematopoietic cells were eliminated from 
the analysis by gating cells on cytokeratin-FITC versus CD45-PercP dot plots (C) and 
CD44
+
/CD24
-
/Ck
+
/CD45
-
 breast cells were identified by gating cells on CD44-APC versus CD24-
PE. Negative control: cells labeled only with the IgG1-FITC isotype control. FMO CD44: 
Fluorescence-minus-one control lacking the anti-CD44-APC antibody. FMO CD24: Fluorescence-
minus-one control lacking the anti-CD24-PE antibody. Sample test: cells labeled with anti-C45-
PerCp, anti-Cytokeratin-FITC, anti-CD44-APC and anti-CD24-PE antibodies. Q1: CD44
+
/CD24
-
/Ck
+
/CD45
-
 cells; Q2: CD44
+
/CD24
+
/Ck
+
/CD45
-
 cells; Q3: CD44
-
/CD24
-
/Ck
+
/CD45
-
 cells; Q4: CD44
-
/CD24
+
/Ck
+
/CD45
-
 cells.  
 
DNA extraction 
Genomic DNA was extracted using the Arcturus PicoPure DNA extraction 
Kit (Life Technologies, California, USA), according to the manufacturer’s 
recommendations. Due to the reduced number of cells, only 50 µl of the Extraction 
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Solution was used for each sample. Extracted DNA samples were quantified using 
Nanodrop spectrophotometer (ThermoScientific, Wilmington, DE, USA) and stored 
at -20ºC until library preparation for sequencing.  
 
AmpliSeq™ Cancer Hotspot panel v2 
 
Libraries were generated using the CHPv2 (Thermo Fisher Scientific, 
California, USA). This panel consists of 207 amplicons covering over 20 000 
bases of 50 genes with known cancer associations. DNA concentration of each 
sample was re-measured using Qubit 3.0 fluorometer (Thermo Fisher Scientific). 
All samples were processed in a vacuum concentrator (Thermo Fisher Scientific) 
to increase DNA concentration at room temperature and default vacuum pressure, 
with constant monitoring. Starting DNA (1–10 ng) from each sample was used to 
prepare barcoded libraries using IonXpress barcoded adapters (Thermo Fisher 
Scientific). Recommended additional cycling conditions were used for libraries with 
low molarities (<50 pM). The Ion Ampliseq library kit (Thermo Fisher Scientific) 
was used as per the manufacturer’s recommendations. Libraries were further 
processed on Ion Chef System and the resulting Ion 540 chip was sequenced on 
Ion S5 XL System (Thermo Fisher Scientific).   
 
Data analysis  
Data from the S5 XL run was processed using the Ion Torrent platform 
specific pipeline software Torrent Suite v5.0.2. Reads generated were aligned 
using the Torrent Mapping Alignment Program (TMAP) - to the human reference 
genome build 19 (hg19). After alignment, coverage statistics were generated using 
Coverage Analysis plugin v5.0 (Life Technologies). Ion Reporter v5.0 was used to 
call somatic SNPs, multi-nucleotide polymorphisms (MNPs), single-nucleotide 
variants (SNVs) insertions, deletions, (INDELs) and block substitutions. FASTQ 
and/or BAM files were generated using the Torrent Suit plugin FileExporter v5.0 
and use for Integrative Genomic Viewer (IGV).   
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Immunohistochemistry 
E-Cadherin and vimentin IHC was performed on the FFPE blocks 
correspondent to malignant lesions (n=28). The staining method was carried out 
as previously described [8] with the monoclonal antibodies E-Cadherin (clone 
4A2C7, Dilution: 1/50, Invitrogen, UK) and vimentin (clone V9, Dilution: 1/500, 
Dako, Denmark). The reaction obtained in all samples was microscopically 
analyzed (Olympus U-SPO3, Olympus Corporation, Japan) by one pathologist 
(CL). For E-Cadherin, the semi-quantitative evaluation method was applied as 
previously described [8] with only 2 categories considered (negative/low 
expression and high expression). For vimentin only presence or absence of 
immunoexpression was considered.    
 
Statistical analysis 
Statistical analyses of the flow cytometry and immunohistochemistry results 
were performed using IBM SPSS Statistics version 20.0 software. Sample 
distributions were compared using Kruskal-Wallis or Mann-Whitney U tests. 
Pearson’s Chi-Square was used to evaluate the differences between categorical 
variables. The Spearman’s rank correlation coefficient was used to evaluate the 
relationship between variables. The Kaplan-Meier method was used for univariate 
survival analysis. Statistical significance was considered for P < 0.05. 
 
Results 
 
Median Fluorescence Intensity of CD44, CD24 and Ck in breast samples 
CD44, CD24 and Ck expression was observed in both non-malignant and 
malignant samples. For each sample, the median fluorescence intensity for CD44, 
CD24 and Ck within mammary epithelial cells was retrieved. Regarding the cell-
surface marker CD44, the median fluorescence intensity was higher in malignant 
samples when compared with non-malignant ones, but was not statistically 
significant. For the fluorescence intensity of CD24 and Ck, a significant lower 
median fluorescence intensity was observed in malignant samples when 
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compared with non-malignant ones (P = 0.032 and P = 0.030, respectively, Table 
1).  
Table 1. Mean fluorescence intensities of CD44, CD24 and Cytokeratin expression in breast tissue 
samples  
Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; SEM standard error of the 
mean 
Values were approximated to the nearest full unit 
a 
Non-malignant vs Malignant 
b 
DCIS vs IDC 
 
 
CD44+/CD24-/Ck+/CD45- cell population in breast samples and association with 
clinicopathological variables 
We were able to identify CD44+/CD24-/Ck+/CD45- breast cells in non-
malignant (Fig. 2A), DCIS (Fig. 2B) and IDC (Fig. 2C) lesions. Due to the low 
percentages of CD44+/CD24-/Ck+/CD45- cells identified in several samples, raw 
percentages of these cells for statistical analysis were preserved instead of using 
cut-off values, except for prevalence description. Actually, for non-malignant 
samples, percentages of CD44+/CD24-/Ck+/CD45- cells ranged from 0% to 7% 
with 12 cases having more than 1%. Regarding DCIS, CD44+/CD24-/Ck+/CD45- 
cells ranged from 2.6% to 14.1% with 3 cases having ≥10%. As for IDC lesions, 
these cells ranged from 0% to 53.8%, where 30.4% of the samples were negative 
or presented scattered cells and the same percentage of cases displayed ≥10% of 
these cells (Table 2).  
As also presented in table 2, malignant samples had a higher mean 
percentage of CD44+/CD24-/Ck+/CD45- cells when compared to non-malignant 
samples (P = 0.007). Within the malignant cases, no significant differences were 
observed between DCIS and IDC lesions.    
 
 
 
  CD44 intensity CD24 intensity Ck intensity 
Characteristics n (%) Mean ± SEM 
(%) 
P 
 
Mean ± SEM 
(%) 
P 
 
Mean ± SEM 
(%) 
P 
 
Type of lesion        
Non-malignant 21 (43) 2302 ± 362 
0.337
a
 
11369 ± 2890 
0.032
a
 
65149 ± 11300 
0.030
a
 
Malignant 28 (57) 3061 ± 619 5480 ± 620 39077  ± 5558 
    DCIS 5 (18) 2337 ± 887 
0.595
b
 
5903 ± 2503 
0.809
b
 
42913 ± 19191 
0.822
b
 
    IDC 23 (82) 3219 ± 732 5388 ± 832 26920 ± 5613 
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Fig. 2. Identification of CD44
+
/CD24
-
/Ck
+
/CD45
-
 breast cells. (A) fibroadenoma; (B) ductal 
carcinoma in situ (DCIS) and (C) Invasive ductal carcinoma (IDC). Q1: CD44
+
/CD24
-
/Ck
+
/CD45
-
 
cells; Q2: CD44
+
/CD24
+
/Ck
+
/CD45
-
 cells; Q3: CD44
-
/CD24
-
/Ck
+
/CD45
-
 cells; Q4: CD44
-
/CD24
+
/Ck
+
/CD45
-
 cells. 
 
Table 2. Prevalence and mean percentages of CD44
+
/CD24
-
/Ck
+
/CD45
-  
breast cells in breast 
tissue samples 
Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; SEM standard error of the 
mean 
Values were rounded to one decimal place 
 a 
Non-malignant vs Malignant 
 b 
DCIS vs IDC 
 
Regarding the IDC cases, although grade 1 tumors presented a tendency to 
a higher percentage of CD44+/CD24-/Ck+/CD45- cells, no significant correlation 
CD44
+
/CD24
-
/Ck
+
/CD45
-
 breast cells 
Characteristics n (%) <1%, n (%) <10%, n (%) ≥10%, n (%) Mean ± SEM 
(%) 
P 
 
Type of lesion       
Non-malignant 21 (42.9) 9 (42.9) 12 (57.1) 0 (0) 2.0 ± 0.4 
0.007
a
 
Malignant 28 (57.1) 7 (25) 11 (39.3) 10  (35.7) 11.7 ± 2.9 
  DCIS 5 (17.9) 0 (0) 2 (40) 3 (60) 8.9 ± 2.0 
0.832
b
 
  IDC 23 (82.1) 7 (30.4) 9 (39.1) 7 (30.4) 12.2 ± 3.5 
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was observed with tumor grade. However, a significant negative correlation was 
obtained between the mean percentage of these cells and tumor size (P = 0.034, 
Table 3).    
 
Table 3. Mean percentages of CD44
+
/CD24
-
/Ck
+
/CD45
-
 breast cells according to IDC 
clinicopathological markers of clinical progression. 
Abbreviations: IDC, invasive ductal carcinoma; SEM, standard error of the mean 
Values were rounded to one decimal place 
 
Concerning hormone receptor status, an association between the 
percentage of CD44+/CD24-/Ck+/CD45- cells and ER+ was found (P = 0.014) as 
observed in table 4. Furthermore, HER2- tumors also presented a significantly 
higher percentage of CD44+/CD24-/Ck+/CD45- cells than HER2+ breast tumors (P 
= 0.009). For E-Cadherin and vimentin immunostainings (Fig. 3), no significant 
differences were noticed between E-Cadherin expression and the percentage of 
such cells; however and for vimentin expression, the mean percentage of 
CD44+/CD24-/Ck+/CD45- cells was higher in samples Vimentin+ (P = 0.004, Table 
4). 
 
 
 
 
 
 
 
 
                           CD44
+
/CD24
-
/Ck
+
/CD45
-
 breast cells 
Characteristics n (%) Mean ± SEM (%) Correlation coefficient  P  
Grade     
G1 5 (21.7) 16.6 ± 7.6   
 -0.233 
 
G2 11 (47.8) 14.5 ± 6.3 0.284 
G3 7 (30.4) 5.6 ± 2.4  
Tumor size     
T1 11 (47.8) 18.3 ± 5.2  
-0.443 
 
T2 7 (30.4) 8.8 ± 7.6 0.034 
T3 5 (21.7) 4.0 ± 1.5  
Nodal status     
N0 10 (43.5) 19.6 ± 5.6   
N1 6 (26.1) 3.2 ± 1.0 -0.401 0.058 
N2-3 7 (30.4) 9.6 ± 7.4   
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Table 4. Mean percentages of CD44
+
/CD24
-
/Ck
+
/CD45
-
 breast cells according to patient’s hormone 
receptor status and to E-Cadherin and vimentin expression.  
CD44
+
/CD24
-
/Ck
+
/CD45
-
 breast cells 
 DCIS, n (%) IDC, n (%)  Mean ± SEM (%)   P 
ER status     
   ER+ 3 (60.0) 18 (78.3) 14.2 ± 3.7 0.014 
   ER- 2 (40.0) 5 (21.7) 4.1 ± 1.6 
PR status     
   PR+ 3 (60.0) 16 (69.6) 14.1 ± 3.9 0.085 
   PR- 2 (40.0) 7 (30.4) 6.6 ± 3.2 
HER2 status     
   HER2+ 4 (80.0) 5 (21.7) 6.5 ± 2.1 0.009 
   HER2- 1 (20.0) 18 (78.3) 14.1 ± 4.1 
Ki-67 status     
   Low 2 (40.0) 15 (65.2) 12.8 ± 4.1 0.214 
   High 
Vimentin status 
   Negative 
   Positive 
E-Cadherin 
  Negative/low expression 
  High expression 
3 (60.0) 
 
0(0) 
5 (100) 
 
4 (80.0) 
1 (20.0) 
8 (34.8) 
 
14 (60.9) 
9 (39.1) 
 
16 (69.6) 
7 (30.4) 
9.9 ± 3.9 
 
5.6 ± 2.9 
17.6 ± 4.6 
 
11.6 ± 3.6 
11.9 ± 5.3 
 
 
0.004 
 
 
0.995 
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 
receptor; SEM standard error of the mean 
Values were rounded to one decimal place 
Fig. 3: Representative images of the immunohistochemistry for E-cadherin and Vimentin in breast 
tissue sections. (A) and (C) Negative and positive expression of E-Cadherin, respectively. (B) and 
(D) Negative and positive expression of vimentin, respectively.   
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Mutations identified in CD44+/CD24-/Ck+/CD45- breast cells  
To determine the mutations associated to CD44+/CD24-/Ck+/CD45- breast 
cells from non-proliferative to invasive lesions, all cell populations were sequenced 
(n=6) using the CHPv2. Although the low numbers of CD44+/CD24-/Ck+/CD45- 
breast cells collected from the six mastectomy samples, we were able to obtain 
adequate libraries from all samples and subsequently sequenced without whole-
genome amplification.  
All target regions could be covered adequately (Table 5) with a mean read 
length of 106 bp except for one sample which showed a mean coverage below 
100x and was consequently excluded from the analysis. All other samples were 
covered ≥500x on average. Non-synonymous somatic mutations identified in each 
sample are described in Table 6. The sample corresponding to a fibroadenoma 
only showed a SNP. In the pure DCIS samples, one frameshift mutation in the 
TP53 gene was found. In DCIS within IDC, four different mutations were detected 
in the NOTCH1, PTEN, Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) 
and AKT1 genes. Regarding the invasive cases, the luminal tumor harbored only 
one mutation in the CSF1R gene; for the triple-negative breast tumor, three 
mutations were identified affecting the RET, TP53 and SWI/SNF Related, Matrix 
Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1 
(SMARCB1) genes.  
 
Table 5. Characteristics of the Targeted Sequencing applied in the DNA samples of CD44
+
/CD24
-
/Ck
+
/CD45
-
 breast cells sorted from 6 mastectomies samples.   
CD44
+
/CD24
-
/Ck
+
/CD45
-
 breast cells 
Sample Number of sorted cells Mapped reads On Target (%) Uniformity (%) 
FAD 126 2265645 96.3 99.6 
Pure DCIS 553 1737683 95.8 97.9 
DCIS within IDC 717 1291288 0.3 39.1 
DCIS within IDC 1511 1408814 99.6 89.2 
IDC (Luminal) 147 2775810 96.6 99.6 
IDC (Triple-negative) 1900 2417404 98.7 92.8 
Abbreviations: FAD, fibroadenoma; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma 
Percentages were rounded to one decimal place 
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Table 6 Description of mutations identified in CD44
+
/CD24
-
/Ck
+
/CD45
-
 breast cells of each mastectomy sample. 
Abbreviations: FAD, fibroadenoma; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; SNP, single-nucleotide polymorphism; SNV, 
single.nucleotide variant; INDEL, insertion/deletion; UN Unknown. 
 
 
 
 
 
 
Sample Locus Genotype Type Genes Variant ID Transcript Coding Amino acid 
change 
Variant effect 
Fad chr4:55593464 A/C SNP KIT COSM28026 NM_000222.2 c.1621A>C p.Met541Leu Missense 
Pure DCIS chr17:7577099 CTCCCAGGACA
GGCACAAACAC
GCACCTCAAAG
CTGTTCCG/C 
INDEL TP53 UN 
 
NM_000546.5 c.799_838del40 p.Arg267fs Frameshift Deletion 
DCIS within IDC chr9:139390819 G/A SNV NOTCH1 UN NM_017617.3 c.7372C>T p.Pro2458Ser Missense 
chr10:89720802 TTAC/T INDEL PTEN COSM4982 NM_000314.4 c.954_956delTAC p.Thr319del Non frameshift 
Deletion 
chr11:533908 T/C SNV HRAS UN NM_001130442.1 c.148A>G p.Thr50Ala Missense 
chr14:105246539 T/C SNV AKT1 UN 
 
NM_001014431.1 c.61A>G p.Thr21Ala Missense 
IDC (Luminal) chr5:149433688 C/T SNV CSF1R 
 
UN NM_014983.2 
 
c.2863G>A p.Glu955Lys Missense 
IDC (Triple-negative) chr10:43615605 T/C SNV RET UN NM_020975.4 c.2684T>C p.Leu895Ser Missense 
chr17:7577556 
 
CAGG/AAGG 
 
SNV 
 
TP53 
 
COSM10810 
 
NM_000546.5 
 
c.725G>T 
 
p.Cys242Phe 
 
Missense 
 
chr22:24145534 G/A SNV SMARCB1 
 
UN 
 
NM_003073.3 c.553G>A p.Val185Met Missense 
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Discussion 
Considering that CD44+/CD24-/low cells were already proved to be tumor 
initiating cells in breast cancer [10], our first purpose was to characterize 
CD44+/CD24-/Ck+/CD45- breast cells in non-malignant and malignant lesions. 
Regarding the results obtained, the median fluorescence intensity was significantly 
lower in malignant samples when compared with non-malignant ones for both 
CD24 and Ck. Considering that CD24 has been identified as a marker of 
differentiated normal mammary epithelial cells [10] and that along breast 
tumorigenesis, malignant cells become poorly differentiated (as seen with the 
lower fluorescence intensity of Ck), such result would then be expected.    
 The gradual enrichment of CD44+/CD24-/Ck+/CD45- breast cells from non-
malignant lesions to DCIS and IDC lesions supports the notion of a tumor-initiation 
capability, which can be explained by the tenets of the CSC model. In fact, studies 
by others have already demonstrated the existence of CD44+/CD24-/low breast cells 
in DCIS lesions but more importantly, that these cells exhibited enhanced invasive 
properties [25, 26].  
   Among the invasive cases, a negative correlation with the mean 
percentages of CD44+/CD24-/Ck+/CD45- tumor cells and tumor size was obtained. 
The concept that BCSCs give rise to non-tumorigenic cancer cells that form a 
tumor mass through a symmetric division can explain the lower number of 
CD44+/CD24-/Ck+/CD45- tumor cells seen in larger tumors.   
 Furthermore, and regarding the distribution of such cells according to 
hormone receptor status, a significant association with ER+ and HER2- was 
obtained. This association can be misreported due to the small number of ER- 
breast cancers used in this study. Nonetheless, and despite the reported 
association of CD44+/CD24-/low cells with basal-like breast tumors, other studies 
did not find any association between this phenotype and hormone receptor status 
[1, 27]. Moreover, low expression of CD24 was also demonstrated to be 
associated with ER positivity and HER2 negativity, what can in part explain our 
results obtained [28, 29].   
 Additionally, vimentin+ cases presented a higher mean percentage of 
CD44+/CD24-/Ck+/CD45- tumor cells when compared with cases negative for this 
myoepithelial marker. Vimentin has recently been shown to be an important EMT 
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marker and a critical regulator of mesenchymal cell migration [30]. EMT is a 
developmental process during which epithelial cells lose epithelial characteristics 
and acquire mesenchymal properties by the disassembly of cell-cell junctions, loss 
of cell polarity and reorganization of the cytoskeleton, thereby acquiring increased 
motility. Because EMT endows cancer cells with migratory and invasive properties, 
it is implicated in tumor invasion and metastatic dissemination and has been linked 
with BCSCs [15]. Thus, our result can suggest a close association with 
CD44+/CD24-/Ck+/CD45- tumor cells and the acquisition of an EMT state during 
breast cancer progression. What is noteworthy, however, is the fact that all DCIS 
samples were positive for vimentin and all of them contained CD44+/CD24-
/Ck+/CD45- tumor cells. Because EMT promotes tumor invasion by facilitating 
tumor cells to escape from the rigid constraints of the surrounding tissue 
architecture, such as basement membrane, the EMT state acquisition from these 
cells could be equally important for the progression to an invasive state [31].  
 Consistent with the notion that genetic alterations may lead to genomic 
instability and cancer development and considering the properties of BCSCs, 
which were already demonstrated to have several signaling pathways 
dysregulated [14-18], our second purpose was to identify, trough NGS, which 
somatic mutations were associated to CD44+/CD24-/Ck+/CD45- cells in different 
breast lesions. We were able to identify somatic mutations in DNA samples from 
as little as 126 CD44+/CD24-/Ck+/CD45- cells without the need to recur to whole-
genome amplification technologies, thus reducing sequencing errors. Besides that, 
the CHPv2 assay was recently proved to be highly sensitive for manual inspection 
of such type of mutations and to be a reliable test in cancer diagnostic using both 
FFPE and frozen tissues even with low input DNA [32].  
 Regarding our samples, only a SNP in the tyrosine-protein kinase KIT gene 
was identified in our cell population taken from a fibroadenoma. Even with the 
notion that this tyrosine-protein kinase plays an essential role in stem cell 
maintenance [33], the clinical significance of this SNP in breast cancer remains 
unknown.  
 In pure DCIS, a frameshift deletion of TP53 gene was found to be 
associated to CD44+/CD24-/Ck+/CD45- tumor cells. In fact, loss of p53 in 
mammary epithelial cells was shown to activate the EMT program and to increase 
mammary stem cell population leading to the development of a high grade tumor 
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[34]. Considering that this gene is frequently mutated in breast cancer, it is 
plausible to assume that this frameshift deletion can aid CD44+/CD24-/Ck+/CD45- 
cells in the development and progression to a malignant phenotype.           
 In DCIS within IDC, four different mutations were found to be associated to 
this phenotype affecting NOTCH1, HRAS, PTEN, and AKT1 genes. Regarding the 
first one, aberrant activation of Notch signaling pathway was found to be an early 
event in breast cancer and high expression of NOTCH1 was seen to increase self-
renewal capacity of BCSCs in DCIS lesions, contributing for breast cancer 
progression [35]. Hyperactivation of HRAS, in turn, was shown to induce cancer 
development in MCF10A human breast epithelial cells and to prompt EMT in 
CSCs via upregulation of vimentin [29]. In this way, the two missense mutations 
identified in these genes can eventually contribute for breast cancer progression of 
CD44+/CD24-/Ck+/CD45- tumor cells by increasing their self-renewal ability and to 
promote the acquisition of an EMT state considering that vimentin was seen to be 
expressed in this particular case. As for PTEN, where a known INDEL was 
identified, an interesting study demonstrated that upon the inhibition of PTEN, the 
cancer stem-like fraction (characterized by CD44+/CD24-/low cells) within the human 
breast cancer cell line MCF7 was significantly increased inducing activation of 
AKT in these cells, another gene found to be mutated in this case. In fact, 
increased AKT phosphorylation was shown to regulate BCSC expansion [36]. 
Besides that, vimentin phosphorylation regulated by AKT1 leads to its enhanced 
ability to induce motility and invasion [37]. Taken together, the mutations identified 
in these genes can strongly contribute for the expansion of CD44+/CD24-
/Ck+/CD45- tumor cells as well as for the progression of these cells towards an 
invasive state.  
   Concerning the invasive samples, only one mutation affecting the CSF1R 
gene was identified in CD44+/CD24-/Ck+/CD45- tumor cells from the luminal tumor, 
probably due to the low number of these sorted cells (n=126). However, the 
Colony-stimulating factor-1 (CSF1) and its receptor CSF1R have been implicated 
in the pathogenesis and progression of various types of cancer, including breast 
cancer [38]. Indeed, high expression of CSF1 and CSFR1 in normal mammary 
epithelial cells was demonstrated to result in a dramatic stimulation of the invasive 
phenotype and anchorage-independent growth of these cells [39]. As referred in 
this study, breast tumors are comprised of phenotypically diverse populations of 
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breast cancer cells. Among them, BCSCs are important for tumor growth and 
metastasis. Thus, it is plausible to assume that mutations in the CSF1R gene can 
potentially stimulate CD44+/CD24-/Ck+/CD45- tumor cells to do so.     
 Finally, cells sorted from the triple-negative tumor harbored three different 
mutations. TP53 gene alterations occur in the majority of triple-negative tumors. 
[40]. Considering the reasons presented above between TP53 mutations and the 
CD44+/CD24-/low phenotype, this known missense mutation found in this cell 
population from this sample can have a crucial role for the progression of 
CD44+/CD24-/Ck+/CD45- tumor cells along breast tumorigenesis. Concerning the 
mutation affecting the RET gene, its overexpression has recently been identified in 
triple-negative tumors [41]. RET is known to influence cellular proliferation, 
differentiation and migration [42]. Whether this identified mutation affects the 
behavior of BCSCs is currently unknown. Further studies are required to assess a 
possible association between mutated RET and the CD44+/CD24-/Ck+/CD45- 
phenotype. Conversely, SMARCB1 is considered to be highly conserved in solid 
tumors [43]. In fact, little is known about the effects of its deregulation in breast 
cancer Again, further demonstrations of existent mutations affecting this gene in 
breast cancer, specifically in BCSCs are required.  
 Apart from the mutations found in this study is the evidence that in any case 
where CD44+/CD24-/Ck+/CD45- tumor cells were identified and sorted, the same 
mutation was noticed. Such marked heterogeneity can be the reason for the 
relative low impact of new pharmacological drugs targeting directly or indirectly 
BCSCs in breast cancer patients. Considering that the DCIS within IDC and IDC 
samples were taken from advanced breast cancers (grade 2 and 3, respectively), 
clonal evolution in BCSCs can be fundamentally important for such variability of 
mutations that were found. Important factors like time, tumor microenvironment 
and hormone exposure can trigger clonal selection among different populations of 
BCSCs harboring different mutations. Indeed, all genes that were found to be 
mutated in this study can play crucial roles for the development and transformation 
of CD44+/CD24-/Ck+/CD45- breast cells into a malignant phenotype, for stemness 
maintenance and acquisition of an EMT state. 
Nonetheless, the lack of validation precludes us to conclude that we have 
truly identified stem cells and BCSCs. Moreover, our small number of cases used 
for this study limits some important conclusions like the statistical relevance 
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obtained for hormone receptor status or regarding the inter- and intra-tumor 
heterogeneity. 
 The use of massive parallel sequencing technology for this type of 
application revealed to be extremely effective even when using small amounts of 
DNA extracted from a low number of cells. Thus, such approach can be of 
particular interest to identify which mutations affects BCSCs for each patient in 
order to achieve more effective therapies for breast cancer treatment. Additional 
studies are now required involving functional analysis to infer about the 
tumorigenic effect of the most relevant mutations found. Besides that, the same 
approach is also needed using a larger cohort comprehending primary tumors and 
their correspondent metastasis to deepen the knowledge regarding the breast 
cancer progression of BCSCs and also to design an effective mutational profile of 
these cells.  
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1. General Discussion 
 
A lot has been done in breast cancer research in order to reduce the high 
rates of incidence and mortality associated to this disease. From more advanced 
screening programs to more effective treatments, breast cancer continues to be 
the major concern in women health. Nonetheless, and despite all efforts, several 
limitations still exist preventing an elucidative comprehension regarding the 
progression of breast cancer cells as well as their ability to resist to certain 
therapeutic agents and to colonize other parts of the body.       
Over the last decade, the notion that tumors are maintained by their own 
SCs, the so-called CSCs, has created great excitement in the research community 
[1]. In fact, the CSC hypothesis has become increasingly popular after the 
identification of defined tumor subsets endowed with tumorigenic activity and 
exhibiting phenotypic features of normal SCs. After its discovery in leukaemia, 
CSCs were isolated in many solid malignancies [2]. In breast cancer, the first 
report was by Al-Hajj et al where they isolated BCSCs designated as 
CD44+/CD24-/low lineage-. As few as 100 of these cells were sufficient to generate 
tumors when xenotransplanted into NOD/SCID mice, whereas tens of thousands 
of cells with alternative phenotypes failed to do so [3]. With such demonstration, a 
plethora of studies were published describing the impact of BCSCs identified by 
these established BCSC markers, as tumor initiating cells in breast cancer with 
high propensity to metastasize and to be resistant to therapeutic treatments [4-6]. 
However, and due to the high levels of heterogeneity associated with this disease, 
some breast cancers were shown not to contain any CD44+/CD24-/low lineage- 
breast cell. As a consequence, other markers like ALDH1 or CD133 were reported 
[7, 8]. Indeed, a multiplexed method of in situ identification of putative BCSCs 
characterized by CD44 and ALDH1 was able to identify high risk patients in breast 
cancer [9]. Moreover, subpopulations of ALDH1high/CD44+ cells were recently 
identified in several human breast cancer cell lines which contributed to both 
chemotherapy and radiation resistance, suggesting a much broader role for 
ALDH1 in treatment response than previously reported [10, 11].   
With this in mind and regarding the sequential progression of breast 
cancers seen from non-malignant to malignant lesions [12], we analyzed, by IHC, 
the expression of ALDH1 and CD44 in different breast lesions. What was 
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noteworthy in this study was the higher combined expression of these markers 
observed in DCIS when compared with IDCs. Looking at the concepts of the CSC 
model, cancers originate from the malignant transformation of an adult stem or 
progenitor cell through the deregulation of the normally tightly-regulated self-
renewal program [13]. Regarding the important roles of CD44 (self-renewal, niche 
preparation and resistance to apoptosis) and ALDH1 (self-renewal, SC 
proliferation control, protection against oxidative insults), both markers can be 
responsible for the malignant transformation of BSCs into BCSCs. Moreover, if 
CSCs have the ability to self-renew and differentiate generating non-tumorigenic 
cancer cells that form a tumor mass [14], only a few cells would be enough for 
invasion, explaining thus the lower combined expression of these markers in IDCs. 
Associated to this explanation is the hypothetical model of an evolutionary 
bottleneck upon the transition from DCIS to IDC [15]. BCSCs can be subjected to 
a clonal selection during the progression to an invasive state where only a 
subpopulation of these cells will have the ability to invade. In other words, the low 
number of BCSCs that promote invasiveness can be the consequence of a clonal 
selection upon the transition of DCIS to IDC.    
 Among the important features of CSCs, we turned our attention to a 
particular one: the recent observation that CSCs mainly exist in a quiescent state. 
The isolation of adult SCs has revealed new insights about the epigenetic, 
transcriptional and post-transcriptional control of quiescence. It was proposed that 
an actively preserved state of quiescence would exist being regulated by signaling 
pathways that sustain a controlled state, allowing thus a rapid activation [16]. 
Besides that, SC quiescence is highly relevant for cancer therapy since that 
quiescent CSCs are often resistant to both chemotherapy and targeted therapies 
contributing to relapse following discontinuation of therapy [17]. In fact and more 
recently, such dormant cells were identified in pancreatic adenocarcinoma and 
shown to be enriched for CSC markers such as CD133, CD44, CD24 and ALDH1 
[16]. Regarding the results obtained in the first study, we developed a triple-
immunostaining method to identify CD44+/ALDH1+ breast cells in their quiescent 
state (Ki-67-) in a cohort comprehending different breast lesions. 
 As expected, the mean percentage of CD44+/ALDH1+/Ki-67- breast cells 
was higher in DCIS when compared with IDCs. Interestingly and apart from the 
number of these cells, some isolated pools of CD44+/ALDH1+/Ki-67- tumor cells 
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were detected in DCIS and IDCs, highlighting another concept of the CSC model: 
the existence of a CSC niche. This specific niche comprehend different types of 
cells (niche cells, stromal cells, immune cells and vasculature) that surrounds the 
CSCs and also, secreted factors derived from these cells, which offer a “fertile 
territory” for CSCs to propagate [18]. Hence, for CSCs that exhibit stem cell-like 
features and have the capability to regenerate the bulk of tumor cells without 
losing their self-renewal propensity, the CSC niche act as a microenvironment 
regulatory system for these cells [19]. Both CD44 and ALDH1 display important 
roles in the regulation of BCSCs and the maintenance of their stemness properties 
[15]. Thus, CD44+/ALDH1+/Ki-67- breast cells identified in the malignant tissues 
can take advantage of the niche that supports normal SCs to progress along the 
tumorigenic process. Another pertinent point is their existence in a quiescent state. 
Quiescent SCs are able to respond to stimuli that originate from their niche 
environment by activating and entering the cell cycle [20]. In a similar way, 
quiescent CSCs may be prompted for activation by specific energetically favorable 
mechanisms from their niche that are compatible with the low metabolic state of 
quiescence [20]. Also like normal SCs, the detachment of CSCs from their niche 
leads to an asymmetric or symmetric division, another ability sustained by the 
roles of CD44 and ALDH1 [15]. In fact, this ability can also explain the negative 
correlation obtained from the mean percentages of CD44+/ALDH1+/Ki-67- tumor 
cells with tumor size. If these cells are capable to differentiate generating non-
tumorigenic cancer cells, large tumors will proportionally have less tumor initiating 
cells than smaller ones.  
 Furthermore, the observation that CD44+/ALDH1+/Ki-67- tumor cells can 
favor distant metastasis and are able to predict OS in breast cancer is also of 
great importance. These BCSCs markers were already described to be 
determinant for treatment resistance, recurrences and metastasis development 
due to the expression of high levels of therapy-resistance proteins [11, 21]. ALDH1 
activity has been shown to render cancer cells exquisitely resistant to some 
chemotherapy agents mainly due to its well-characterized role in differentiation 
through the retinoic acid pathway [22, 23]. CD44 plays a potent role in every 
aspects of breast cancer involving cancer cell proliferation, progression and 
metastasis. High levels of CD44 expression enhance the invasion of BCSCs; 
CD44s dynamic association with cytoskeletal proteins enables motility, while CD44 
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clustering also facilitates localization to secondary metastatic sites through 
CD44/Hyaluronan acid binding [24]. With such features, it is plausible to assume 
that both CD44 and ALDH1 can play important roles for the resistance and 
dissemination of BCSCs.  
Moreover, quiescence may also have a determinant role in tumor 
progression and relapse. Several chemotherapeutic agents as well as 
radiotherapy work by inducing DNA damage. Thus, cells that have the ability to 
repair DNA damages are more prone to survive chemotherapy. Regarding the 
properties of quiescence, quiescent cells may have the potential and/or time to 
repair the damage inflected to them. Although quiescence is not an essential 
characteristic that defines SCs, in BCSCs, there is increased expression of DNA 
repair genes, indicating that high DNA repair pathway activity may aid in making 
CSCs resistant to tumor therapy [16]. 
Apart from the roles of CD44 and ALDH1 and the effects of cell dormancy in 
breast cancer progression, is the recent suggestion of a co-existence between the 
CSC model and the clonal evolution model. From a different perspective of what 
was proposed by Clevers in 2011, tumor progression has been related to 
‘Darwinian’ evolution. The expansion of an established tumor can be explained by 
the generation of new CSC clones as a result from mutations, genetic instability or 
epigenetic alterations. The prevalence of new CSCs and their clones will be 
determined by different selective pressures (nutritional or immune status, 
oxygenation and therapy) that modify the tumor microenvironment. If selected, 
these cells can be responsible for tumor relapse or metastasis (Figure 1) [25].  
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Figure 1. Clonal co-existence. Most tumors have their origin in a single mutated cell so the cells in 
the resultant clone will have the same founder mutation (black asterisk). During progression, 
different selection pressures (nutritional or immune status, oxygenation, therapy) could result in the 
emergence of new clones through genetic and epigenetic alteration. Adapted from [25].  
 
Despite these novel findings regarding the identification of CD44+/ALDH1+ 
breast cells in their quiescent state (Ki-67-), the CD44+/CD24-/low phenotype 
continues to be by far the most studied phenotype in breast cancer having several 
signaling pathways demonstrated to be dysregulated [6, 26-29]. Moreover, this 
phenotype was also demonstrated to harbor potential mechanisms of 
chemotherapy and radiation resistance including the presence of lower 
concentration of reactive oxygen species, cell dormancy, efficient DNA repair 
mechanisms, overexpression of EMT markers, and STAT1 and STAT3 signaling 
activation [30, 31, 28-29]. With all this knowledge, the use of more advanced 
technologies like NGS that could deepen the molecular characterization of this 
phenotype can be seen as an interesting approach.     
 NGS has recently been used for the analysis of the molecular features of 
early stage breast cancer, leading to a genomic portrait of this disease. Within 
such portrait, TP53 and PIK3CA mutations are the most frequent genomic 
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alterations. Besides these mutated genes, clinical relevance of PTEN mutations 
and deletions as well as AKT1, BRCA1 or BRCA2 mutations is also highlighted 
[32]. With the current availability of standardized NGS kits providing reliable 
sequencing results in routine cancer diagnostics [33, 34], we used the CHPv2 to 
analyze the molecular features of CD44+/CD24-/Ck+/CD45- cells in different breast 
lesions.   
 Considering that we used FCM and FACS technologies to identify and 
isolate CD44+/CD24-/Ck+/CD45- breast cells, we have also characterized these 
cells by FCM from a cohort comprehending non-malignant and malignant lesions. 
From this analysis, the gradual enrichment of CD44+/CD24-/Ck+/CD45- breast cells 
observed from benign to IDC lesions supports the idea of a tumor initiation 
capability from these cells. Interestingly and similar to the CD44+/ALDH1+/Ki-67- 
phenotype, a negative correlation was obtained from the mean percentages of 
CD44+/CD24-/Ck+/CD45- tumor cells with tumor size, strengthening the idea that 
BCSCs are able to differentiate in non-tumorigenic cells that form a tumor mass 
[14].  
 Additionally and with the recent observations that the CD44+/CD24-/low 
phenotype possess an epithelial-mesenchymal transition (EMT) capacity, vimentin 
and E-Cadherin expression was analyzed by IHC. Indeed, the association seen 
between vimentin expression and the mean percentages of CD44+/CD24-
/Ck+/CD45- tumor cells also strength the notion of an EMT state acquisition from 
these cells during breast cancer progression [31].   
 The novelty in this study was the application of MPS technologies in the 
CSC field. Despite the low number of cases used for this purpose, we were able to 
detect somatic mutations in as little as 126 CD44+/CD24-/Ck+/CD45- tumor cells 
without the need to recur to whole-genome amplification technologies.  
 In DCIS lesions, mutations affecting the TP53, NOTCH1, HRAS, PTEN and 
AKT1 genes were found to be associated to the CD44+/CD24-/Ck+/CD45- 
phenotype. Considering the effects of such altered genes in breast tumorigenesis 
[35-38], these mutations can strongly contribute for the expansion of CD44+/CD24-
/Ck+/CD45- tumor cells as well as for the progression of these cells towards an 
invasive state. 
   Concerning the invasive samples, only one mutation affecting the CSF1R 
gene was identified in CD44+/CD24-/Ck+/CD45- tumor cells isolated from the 
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luminal tumor. Such mutation can potentially stimulate these cells to proliferate 
and to colonize other parts of the body [39].  
 Finally, cells sorted from the triple-negative tumor harbored three different 
mutations affecting the TP53, RET and SMARCB1 genes. While TP53 alterations 
are well characterized in breast cancer [40], the functions of altered RET and 
SMARCB1 genes in breast cancer are still undefined.  
 Looking at the number of mutations that was found in isolated CD44+/CD24-
/Ck+/CD45- cells from each sample, the DCIS within IDC lesion presented more 
mutations than the IDC lesions. Such result can be explained, once again, by the 
hypothetical model of an evolutionary bottleneck upon the transition from DCIS to 
IDC. Assuming the existence of different subpopulations of BCSCs, clonal 
selection may favor those who harbor advantageous mutations (driver mutations) 
for the progression to an invasive state.   
Moreover, clonal evolution may also explain the variability of the mutations 
that were found in isolated CD44+/CD24-/Ck+/CD45- tumor cells from the malignant 
samples. Important factors like time, tumor microenvironment and hormone 
exposure affect breast tumors differently. Hence, it is plausible to assume that 
each population of CD44+/CD24-/Ck+/CD45- tumor cells that was isolated from 
each sample was subjected to different clonal selections harboring thus different 
mutations. With such variability, the identification of driver mutations can be 
extremely challenging. In fact, all genes that were found to be mutated in this 
study, especially in DCIS lesions, can play crucial roles for the development and 
transformation of CD44+/CD24-/Ck+/CD45- breast cells into a malignant 
phenotype, for stemness maintenance and acquisition of an EMT state. 
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2. Conclusions and Future Perspectives  
 
In this thesis work, we aimed to characterize different BCSC phenotypes in 
non-malignant and malignant lesions. With the results obtained from the analysis 
of CD44 and ALDH1 expression in different breast specimens, where a combined 
overexpression of both markers was shown to be significantly higher in DCIS 
when compared with IDCs, a triple-immunostaining was developed. From this 
triple-immunostaining, we characterized the CD44+/ALDH1+/Ki-67- phenotype and 
conclude that CD44+/ALDH1+/Ki-67- tumor cells may have a higher tumorigenic 
effect in breast cancer than CD44+/CD24-/low tumor cells. In fact, the roles of 
ALDH1 and CD44 can be determinant for the behavior of CSCs and the ability to 
resist to chemotherapeutic agents and their dissemination to other parts of the 
body. Besides that, we also conclude that quiescence can have a more 
preponderant role than previously expected which can be crucial for tumor 
progression, resistance to chemotherapeutic agents and metastatic spread of 
BCSCs. From this first characterization, additional studies are now required to 
infer about the tumorigenic and metastatic ability of CD44+/ALDH1+/high tumor cells 
combined with their quiescence status.  
 Considering the well-known features of the CD44+/CD24-/low phenotype in 
breast cancer, we used FCM, FACS and NGS technologies to characterize 
CD44+/CD24-/Ck+/CD45- cells in non-malignant and malignant breast tissues. The 
use of MPS for this type of application revealed to be extremely effective even 
when using small amounts of DNA extracted from a low number of cells. 
Considering the results obtained from this study, functional analyses are now 
needed to determine the tumorigenic effect of the most relevant mutations found in 
this work. Besides that, we conclude that the application of NGS technologies can 
be of particular interest to determine which mutations affect the behavior of 
BCSCs in order to achieve more effective therapies for breast cancer treatment. 
Due to the high levels of heterogeneity existing in breast tumors, a practical 
example would be the application of NGS in isolated BCSCs from primary tumors 
and their corresponding metastases in order to determine which gene is more 
frequently mutated (hotspot mutations) in each BCSC population. 
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In the future and with the continuous improvements of NGS, we will be able 
to deepen our knowledge regarding the progression of BCSCs and also to design 
an effective mutational profile of these cells.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
